


Infectious serology

Infectious serology



Bacteria

Bordetella · Borrelia · Treponema · Chlamydia




For more information on this subject scan the QR code or enter the Quick Link code q008 at www.euroimmun.com

Bordetella

Clinical information: Bordetella pertussis is the causative agent of whooping cough, a disease with 3 stages: 1. Catarrhal stage: mild flu-like symptoms; lasting 1 to 2 weeks; 2. Paroxysmal stage: fits of (staccato-like) coughing spasms with "whooping" sound when inhaling; lasting 2 to 3 weeks; 3. Convalescent stage: slow convalescence, which can take up to several months. Complications such as secondary pneumonia or otitis media are possible, especially in children under the age of 2 years. The disease is known in adults, but is rarely diagnosed, even though coughing adults can infect their surroundings. An infection confers specific immunity, which reduces after several years. The clinical progression of whooping cough depends mainly on the production of the different virulence factors (adhesins and toxins), such as filamentous haemagglutinin (FHA) or pertussis toxin (PT). PT is the only antigen that is exclusively produced by *B. pertussis*. FHA is found in all other *Bordetella* species and also in other bacteria.

Diagnostics: The method of detection for the diagnosis of *Bordetella* infection depends on the disease stage. Direct detection of the pathogen (culture, PCR) is particularly useful in the early stages of infection. Since the pathogen is often no longer detectable after around four weeks following infection, serology gains importance as the disease proceeds. Pathogen-specific antibodies of classes IgA and IgG can generally be detected from the paroxysmal stage. For antibody detection, international reference laboratories recommend test systems that are based on individual purified antigens. The use of antigen mixtures of PT and FHA is obsolete. The quantification of antibody titers should be performed in international units (IU/ml) according to the 1st International Standard of the WHO (1st IS NIBSC Code 06/140). The detection of anti-PT IgG is of particular importance for specific diagnosis of *B. pertussis* infection. A titer of ≥ 100 IU/ml is considered a clear indicator of *B. pertussis* infection. If the anti-PT IgG titer is below 40 IU/ml, acute *B. pertussis* infection is unlikely. In cases of unclear serological anti-PT IgG titers of between ≥ 40 and < 100 IU/ml the investigation of further antibodies such as anti-PT IgA, anti-FHA IgG or IgA can provide additional information. Diagnosis can be confirmed if a significant change in the antibody concentration is found in two consecutive samples. It should be taken into account that a positive antibody result up to one year after vaccination is not a reliable indicator of acute infection.



¹The clinical symptoms and age of the patient should always be taken into account. ²ADR: age-dependent reference ranges for groups of unvaccinated individuals or vaccinated persons whose last vaccination dates back at least one year.

Product overview

Method	Substrate	Application	Order number	Page
ELISA	Highly purified pertussis toxin, PT (IgG antibodies)	Most important serological test; specific for B. pertussis; exclusion of B. parapertussis infections; quantification in IU/ml; interpretation according to 40/100 IU/ml limits	EI 2050-9601 G	176
	Highly purified pertussis toxin, PT (IgA antibodies)	Useful for ambiguous anti-PT IgG titers in the range of ≥40 to <100 IU/ml; quantification in IU/ml	EI 2050-9601 A	176
	Highly purified filamentous haemagglutinin, FHA		EI 2050-9601-3 A/G	176
Blot	PT, FHA, ACT (adenylate cyclase toxin)	Additional qualitative test; antibodies against ACT can indicate a natural infection (ACT is currently not contained in acellular vaccines)	DN 2050-1601 A/G	173



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code q059 at www.euroimmun.com

Bacteria

Bordetella · Borrelia · Treponema · Chlamydia




For more information on this subject scan the QR code or enter the Quick Link code q009 at www.euroimmun.com

Borrelia

Clinical information: Borrelia is the causative agent of Lyme borreliosis, a bacterial disease which is transmitted through bites from ticks of the genus Ixodes and is characterised by a variety of clinical symptoms. The most important human pathogenic Borrelia genospecies are *B. afzelii*, *B. burgdorferi* and *B. garinii*. Lyme borreliosis can manifest itself dermatologically, neurologically or through internal disorders. The radially spreading erythema migrans is a characteristic early symptom, which occurs a few days to several weeks after the infection. This is often accompanied by influenza-like general symptoms, such as fever, shivering, headaches and vomiting. The advanced stage of the disease is characterised by neurological (e.g. facial paresis), cardiac (e.g. myocarditis) and rheumatological (e.g. arthritis) manifestations. In chronic Lyme borreliosis involvement of the joints, epidermis (acrodermatitis chronica atrophicans) and central nervous system as well as fatigue are typically found.

Diagnostics: The diagnosis of Lyme disease is based on the patient anamnesis, clinical findings and the detection of antibodies against Borrelia antigens. For the serological diagnosis of anti-Borrelia-specific antibodies, the German Association for Hygiene and Microbiology (DGHM), the Robert Koch Institute and the CDC (Atlanta, Georgia) call for a two-stage strategy. Firstly, a sensitive screening test (ELISA or IIFT) is performed. Sera with a positive or borderline screening result are investigated further using an immunoblot to differentiate between Borrelia-specific and unspecific reactions. Since antibodies against Borrelia are first produced 2 to 6 weeks after infection, serological tests performed in the early stage of Lyme borreliosis can be negative. Early antibiotic treatment may also prevent antibody production. In suspected cases of neuroborreliosis, the presence of intrathecal synthesis of Borrelia-specific antibodies can be investigated by parallel analysis of a CSF/serum sample.



Product overview

Method	Substrate	Application	Order number	Page
ELISA	Whole antigen, detergent extract of <i>B. burgdorferi</i> , <i>B. garinii</i> and <i>B. afzelii</i> plus recombinant VlsE	IgG ELISA: complete antigen spectrum incl. VlsE, high sensitivity	EI 2132-9601-2 G	176
	Whole antigen, detergent extract of <i>B. burgdorferi</i> , <i>B. garinii</i> and <i>B. afzelii</i>	IgM ELISA: complete antigen spectrum incl. OspC, high sensitivity	EI 2132-9601 M	176
	Mix of recombinant <i>Borrelia</i> antigens incl. VlsE (IgG) or dimeric OspC advanced (IgM)	Especially selected highly specific antigens, reduced cross reactivity	EI 2132-9601-5 G/M	176
Blot	IgG: p18, p19, p20, p21, p58, OspC, p39, p41, p83, LBb, LBa, VlsE Bg, VlsE Bb, VlsE Ba IgM: OspC Bg, OspC Bb, OspC Ba, p39, p41, VlsE Bb	Line blots with diagnostically relevant <i>Borrelia</i> antigens incl. VlsE and OspC from different <i>Borrelia</i> species; simple evaluation	DN 2131-#### G/M	173
	OspC-adv Bsp, OspC-adv Bg, OspC-adv Bb, OspC-adv Ba, p39, p41, VlsE Bb	IgM line blot with rec. <i>Borrelia</i> antigens incl. dimeric OspC advanced from different <i>Borrelia</i> species	DN 2131-####-2 M	173
	Detergent extract of <i>B. afzelii</i> plus rec. VlsE	Complete antigen spectrum; incl. OspC and VlsE	DY 2131-####-1 G/M	174
IFT	Smears of <i>B. afzelii</i> and <i>B. burgdorferi</i> plus VlsE and OspC	Alternative screening test for a small number of samples	FI 2136-####-1 G/M	184



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code q060 at www.euroimmun.com



Bacteria

Bordetella · Borrelia · Treponema · Chlamydia



For more information on this subject scan
the QR code or enter the Quick Link code
q044 at www.euroimmun.com

Treponema pallidum

■ **Clinical information:** *Treponema pallidum* is the pathogenic agent of syphilis (lues), a worldwide occurring, sexually or diaplacentally transmitted infection that is divided into 4 stages. 1. Primary stage: The typical primary manifestation is a clearly defined fibrous or crusted erosion at the site of infection which occurs about three weeks after infection. An ulcer or a hardening of the lesion can develop (hard chancre). Local lymph nodes become swollen within a week. 2. Secondary stage: In addition to a generalised swelling of the lymph nodes, 90% of patients show local or generalised skin disorders. Various organ disorders may develop, for example, ketaritis, iritis, hepatitis, vasculitis, and myocardial disorders. Secondary syphilis is followed by a clinically silent stage (syphilis latens), which can last for years. 3. Tertiary stage: Typical manifestations are large papules and ulcers on the skin and mucous membranes, as well as organ or visceral syphilis, perivasculitis, cardiovascular syphilis, osteitis and periostitis. 4. Quaternary stage: Severe neurological disorders in the form of neurosyphilis can occur up to 30 years after the initial infection. Diaplacental transmission of the pathogen causes congenital syphilis.

■ **Diagnostics:** The diagnosis of syphilis is based on clinical findings according to the disease stage, pathogen detection (from the primary lesion) and serological detection of antibodies against *Treponema pallidum*. The focus of laboratory diagnostics lies in antibody detection, which has proven successful with a three-staged diagnostic procedure consisting of screening, confirmation and evaluation of the disease activity.

Screening can be performed using *Treponema*-specific agglutination tests (TPPA, TPHA) and polyvalent enzyme immunoassays. Useful confirmatory tests are ELISA, FTA-abs test and immunoblots. Due to blood vessel inflammation and tissue damage the activity of the infection correlates with the antibody titer against mitochondrial lipids (cardiolipin), which can be detected using the RPR (rapid plasma reagent) test or VDRL (venereal disease research laboratory) test.

Product overview

Method	Substrate	Application	Order number	Page
ELISA	Antigen mixture of Treponema pallidum (p15, p17, p47 and TmpA)	Screening test; sensitive detection of <i>T. pallidum</i> -specific antibodies (mixed conjugate IgG+IgM); very good correlation with TPHA/TPPA	EI 2111-9601 O	176
	Antigen mixture of Treponema pallidum (p15, p17, p47 and TmpA)	Confirmatory test; separate detection of <i>T. pallidum</i> -specific IgG or IgM antibodies	EI 2111-9601 G/M	176
Blot	Electrophoretically separated antigens of <i>Treponema pallidum</i> plus purified cardiolipin	Confirmatory test and determination of disease activity (differentiation of active from past, healed infection by evaluation of the cardiolipin band)	DY 2111-1601 G/M	174
IFT (FTA-Abs)	Bacterial smears of <i>Treponema pallidum</i>	Confirmatory test; unspecific cross-reacting antibodies are removed by pre-adsorption of samples	FI 2111-#### G/M	184



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code **q101** at www.euroimmun.com



For more information on this subject scan the QR code or enter the Quick Link code q010 at www.euroimmun.com

Chlamydia


Clinical information: The infectious agents *Chlamydia trachomatis*, *Chlamydia pneumoniae* and *Chlamydia psittaci* belong to the human pathogenic *Chlamydia* genus.

Chlamydia trachomatis can cause the following diseases: 1. Trachoma, a tropical eye infection (serotypes A-C); 2. infections of the urogenital tract (serotypes D-K). Non-gonorrhreal urethritis is one of the most common venereal diseases worldwide. Secondary effects of *C. trachomatis* infection can be reactive arthritis, secondary sterility or infertility. 3. Lymphogranuloma venereum (LGV), a rare venereal disease which occurs mainly in tropical areas (serotypes L1-L3).

C. pneumoniae mostly causes infections of the upper respiratory tract and pneumonia. Around half of infections proceed asymptotically. More than 50% of adults have been infected with *Chlamydia pneumoniae* and exhibit antibodies against the pathogen.

C. psittaci is the causative agent of psittacosis, an infection transmitted to humans by domesticated birds. In addition to flu-like symptoms, a life-threatening pneumonia can develop during the course of the infection, which is often accompanied by further organ manifestations.

Diagnostics: Pathogen detection (e.g. using PCR) is the method of choice for the diagnosis of acute urogenital *C. trachomatis* infection. In after-effects associated with *C. trachomatis* such as sterility or reactive arthritis, direct detection of the pathogen is mostly no longer possible. In these cases the investigation of IgA and IgG antibodies is of importance.



Since the diagnosis of *C. pneumoniae* infections in humans by means of symptoms or radiography is not entirely reliable, laboratory diagnostics play a significant role. Detection of the pathogen is useful in the diagnosis of acute infection, but often fails if the infection is older. The analysis of specific *Chlamydia* antibodies (IgA, IgG, IgM) can help with diagnosing primary infection and reinfection. A significant titer increase or seroconversion in two serum samples taken at an interval of several weeks indicates acute infection with *C. pneumoniae*.

Specific antibodies against *Chlamydia* antigens can be detected using MIF (micro-immunofluorescence) assay, ELISA or immunoblot. Since the three *Chlamydia* species have the same cell wall proteins (such as lipopolysaccharids, LPS) and are therefore very similar, cross reactions cannot be ruled out. The inactivation of LPS antigens in the MIF minimises cross reactivity. Type-specific membrane proteins (MOMP: major outer membrane protein) are also suited for species-specific antibody detection.

Product overview

Method	Substrate	Application	Order number	Page
ELISA	Native MOMP (major outer membrane protein) antigen of <i>C. trachomatis</i>	Species-specific detection by use of type-specific MOMP antigen	EI 2191-9601 A/G/M	177
	Cell lysate of <i>C. pneumoniae</i>	Genus-specific detection; sensitive detection of anti- <i>C. pneumoniae</i> antibodies	EI 2192-9601 A/G/M	177
Blot	SDS extract of <i>C. trachomatis</i> plus MOMP antigen	Species-specific detection; separate detection of specific and cross-reacting antibodies; reliable interpretation algorithm	DY 2191-1601-1 A/G	174
IFT (MIF)	Elementary bodies of <i>C. trachomatis</i> , <i>C. pneumoniae</i> , <i>C. psittaci</i> and control BIOCHIP with non-infected cells	Serological gold standard; species-specific detection (cross-reacting LPS antigens are inactivated); simple evaluation due to use of optimised substrates; secure differentiation between unspecific and specific fluorescences by means of control BIOCHIPS	FI 2191-####-3 A/G/M	186



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code **q061** at www.euroimmun.com



Viruses

EBV · HEV




For more information on this subject scan the QR code or enter the Quick Link code q013 at www.euroimmun.com

Epstein-Barr virus

Clinical information: Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis (glandular fever), a febrile disease usually accompanied by pharyngitis and lymphadenopathy, frequently by hepatosplenomegaly and more rarely by exanthema. Recent research results have also shown a connection between EBV infection and the pathogenesis of Burkitt's lymphoma, nasopharyngeal carcinoma (NPC) and multiple sclerosis. In pregnancy, EBV can cause infection of the placenta, leading to damage to the foetal heart, eyes and liver. In children, accompanying infections of the kidney have been observed with symptoms from microscopic haematuria to acute kidney failure.

Diagnostics: Infectious mononucleosis must be differentiated diagnostically from cytomegalic inclusion body disease and toxoplasmosis and, in the case of atypical progress, also from infections with HIV and other pathogens. Since direct evidence of the virus is difficult to obtain, serological parameters routinely serve as diagnostic markers. Parallel determination of antibodies against EBV-CA, EBV-EA, and EBNA-1 not only allows differentiation between acute and past EBV infections, but also provides evidence of chronicity. For determination of antibodies against EBV-CA, EBV-EA, and EBNA-1, indirect immunofluorescence is considered the gold standard. If large groups of patients are being investigated, ELISA is a more suitable method as it is faster and easier to perform. Studies with clinically characterised patients and a group of blood donors demonstrated that the further developed EUROIMMUN Anti-EBV-CA, Anti-EBV-EA-D, and Anti-EBNA-1 ELISAs show a very good correlation with the indirect immunofluorescence test (IIFT). In 90% of cases an acute EBV infection can be characterised serologically by the detection of EBV-CA IgM and an increase in the EBV-CA IgG titer of twofold or more. Serologically difficult constellations, such as persistent anti-EBV-CA IgM antibodies or the absence of specific anti-EBV-CA IgM antibodies in acute infections, can be clarified by measuring the avidity of anti-EBV-CA IgG antibodies.



Product overview

Method	Substrate	Application	Order number	Page
ELISA	Mixture of native EBV capsid antigens (EBV-CA)	IgG/IgA ELISA: complete antigen spectrum ensures high sensitivity and specificity; avidity determination: exclusion of acute infection	EI 2791-9601 A/G EI 2791-9601-1 G	181 181
	Native EBV-CA gp125	IgM ELISA: optimal for the diagnosis of acute infection	EI 2791-9601 M	181
	Recombinant EBNA-1 antigen	High specificity for the late stage of the disease	EI 2793-9601 G	181
	Recombinant EBV early antigen D (EBV-EA-D)	Highly specific recombinant antigen	EI 2795-9601 A/G/M	181
Blot	EBV Profile 2: separate EBV-CA gp125, EBV-CA p19, EBNA-1, p22, EA-D	Line blot with all relevant EBV antigens for the diagnosis and differentiation of early-stage and late-stage EBV infections	DN 2790-####-2 G/M	173
IFT	BIOCHIP sequence: EBV-CA (avidity test, IgG, IgM), EBV-EA, EBNA; infected cells	IIFT is the gold standard for EBV diagnostics; BIOCHIP sequence contains all relevant antigens;	FI 2799-####-1 X	192
	EUROPLUS sequence: EBV-CA (avidity test, IgG, IgM, gp125-Ag, p19-Ag), EBV-EA, EBNA; infected cells	avidity determination: exclusion of acute infection	FI 2799-####-21 X	192



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code q066 at www.euroimmun.com



For more information on this subject scan the QR code or enter the Quick Link code q026 at www.euroimmun.com

Hepatitis E virus

Clinical information: Hepatitis E virus (HEV) is the causative agent of hepatitis E, a worldwide distributed infectious disease. HEV is an uncoated RNA virus of the Hepeviridae family. Four human pathogenic genotypes (1-4) of HEV have so far been described. While genotypes 1 and 2 are exclusively human pathogenic, genotypes 3 and 4 are found in humans and animals. The most common ways of infection include faecal-oral transmission by the consumption of contaminated drinking water or food (endemic areas with low hygienic standards) and zoonotic transmission by the consumption of insufficiently cooked meat from infected animals, e.g. domestic or wild pigs (industrialised countries). Virus-contaminated blood products are also discussed as a potential source of infection for humans.

Infections with HEV usually proceed asymptotically or mildly with unspecific symptoms such as tiredness, loss of appetite, nausea, vomiting, headache and muscle and joint pains. If liver inflammation occurs, it is often self-limiting and heals without any complications. In rare cases hepatitis E can have a fulminant course with acute liver failure. Pregnant women with a history of severe disease courses are particularly at risk. Up to 20% of HEV infections are fatal for the expectant mother (lethality in hepatitis E infections in the total population: 0.5-4%).

Diagnostics: Since the clinical picture of hepatitis E resembles hepatitis A as well as other hepatitides laboratory diagnostic methods are of major importance for diagnosis. Besides PCR detection of viral RNA in blood or stool (recommended method for very early phase of infection) the serological determination of antibodies of class IgA/IgG/IgM against hepatitis E virus is the most important tool for confirming HEV infections. Pathogen-specific antibodies are often detectable at or shortly after the onset of clinical symptoms. A positive IgA and/or IgM result and a significant IgG titer increase in a serum pair (taken at an interval of 8 to 14 days) indicate an acute infection. IgA and IgM anti-HEV titers generally decrease rapidly after infection, while IgG anti-HEV titer often persist for more than 10 years.

Product overview

Method	Substrate	Application	Order number	Page
ELISA	Recombinant target antigens of HEV genotypes 1 and 3	IgG ELISA: first commercial ELISA with quantification in international units (IU/ml) in accordance with WHO standard	EI 2525-9601 G	178
		IgM ELISA: detection of HEV-specific antibodies of class IgM with high specificity and sensitivity	EI 2525-9601 M	178
		IgA ELISA: supplementary test for the diagnosis of acute HEV infection	EI 2525-9601 A	178
		Screening ELISA for parallel determination of IgA, IgG and IgM antibodies against HEV	EI 2525-9601 P	178



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code **q070** at www.euroimmun.com

Special infection diagnostics

CSF diagnostics · TORCH · Tropical infections



For more information on this subject scan the QR code or enter the Quick Link code q031 at www.euroimmun.com


CSF diagnostics

Clinical information: The investigation of cerebrospinal fluid (CSF) is diagnostically decisive in acute or chronic inflammatory processes of the central nervous system (CNS). Acute CNS infections manifest themselves as meningitis (inflammation of the meninges), meningoencephalitis (inflammation of the brain or meninges) or encephalitis (inflammation of the brain). These infections can be caused by bacteria (e.g. Borrelia, Treponema pallidum), viruses (e.g. HSV, VZV, measles virus, TBE virus, EBV) or parasites (e.g. Toxoplasma gondii). CSF analysis also plays a major role in the differential diagnosis of non-infectious diseases such as multiple sclerosis (MS). The detection of intrathecal synthesis of antibodies against measles, rubella and/or varicella zoster viruses (MRZ reaction) is a specific indicator of MS.

Diagnostics: When determining an infection of the CNS it is necessary to differentiate between intrathecally produced antibodies and antibodies which have migrated from the blood into CSF. This is done by measuring the concentrations of pathogen-specific antibodies, corresponding immunoglobulin classes (total IgG, IgM) and albumin in both the CSF and serum of the patient. If an infection of the central nervous system is present, pathogen-specific antibodies accumulate in the CSF. If, however, the infection has not spread to the brain and the blood/CSF barrier is still intact, the distribution of pathogen-specific antibodies in CSF and serum is the same as that of total IgG. The intrathecal pathogen-specific antibody production is defined by the relative CSF/serum quotient CSO_{rel} . (synonym: antibody specificity index). The quotient is calculated from the amount of specific IgG antibodies in total CSF IgG in proportion to the amount of specific IgG antibodies in total serum IgG. A $CSO_{rel} > 1.5$ indicates intrathecal synthesis of pathogen-specific antibodies.

In addition to the determination of specific antibodies, also the investigation of chemokine CXCL13 in CSF is useful for the diagnosis of neuroborreliosis. In patients with acute neuroborreliosis, in early stages of the disease, high concentrations of CXCL13 are frequently observed, often even before antibodies against Borrelia are detectable. CXCL13 determination can help to close the gap between infection and positive antibody test and to diagnose neuroborreliosis at an earlier stage. Moreover, CXCL13 used as activity marker helps to differentiate between acute and past neuroborreliosis. CXCL13 is also suitable as a marker for the disease course after treatment. Its concentration in CSF decreases with successful therapy. It needs to be taken into account that increased CXCL13 values can also be observed in other diseases, in particular in CNS lymphoma, HIV infections and neuro-lues.

Evaluation software: EUROLabCSF is a software for automatic calculation of CSF/serum quotients. For further information see page 58.




Product overview

Method	Substrate	Application	Order number	Page
ELISA	Borrelia	Efficient standardised automation with uniform dilution and incubation conditions; 4-point standard curve for highest accuracy; extended measurement range due to optional additional calibrators (Borrelia, MRZH); very good reproducibility of results for the whole measurement range; excellent agreement with quality assessment results (INSTAND e.V.); automated calculation of results (Excel spreadsheet); CSF/serum control pair available for all ELISAs	EI 2132-9601-L G/M	177
	Measles virus		EI 2610-9601-L G	179
	Rubella virus		EI 2590-9601-L G	179
	Varicella zoster virus (VZV)		EI 2650-9601-L A/G/M	179
	Herpes simplex virus (HSV-1/2)		EI 2531-9601-1 L G	178
	Herpes simplex 1 virus (HSV-1)		EI 2531-9601-L G	178
	Herpes simplex 2 virus (HSV-2)		EI 2532-9601-L G	178
	Cytomegalovirus (CMV)		EI 2570-9601-L G	179
	Mumps virus		EI 2630-9601-L G	179
	Tick-borne encephalitis (TBE)		EI 2661-9601-L G/M	180
	Epstein-Barr virus (EBV-CA)		EI 2791-9601-L G	181
	Treponema pallidum		EI 2111-9601-L G	176
	Toxoplasma gondii		EI 2410-9601-L G	178
Blot	Recombinant and native Borrelia antigens	Additional test for differentiated analysis of antibody band patterns in CSF and serum	DN 2131-1601 G	173
Antigen ELISA	Anti-CXCL13 antibody	Activity and therapy marker in neuroborreliosis	EQ 6811-9601-L	182



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code **q078** at www.euroimmun.com



Special infection diagnostics

CSF diagnostics · TORCH · Tropical infections



For more information on this subject scan the QR code or enter the Quick Link code q043 at www.euroimmun.com

TORCH

■ **Clinical information:** The investigation of antibodies against various infectious agents during pregnancy allows early diagnosis of diseases as well as monitoring of immunity against a pathogenesis that might harm the unborn child. The term TORCH includes all infectious agents that can cause malformation to the foetus. These are Toxoplasma gondii, rubella virus, cytomegalovirus (CMV) and herpes simplex virus (HSV). Infections with these pathogens during pregnancy are most feared.

■ **Diagnostics:** Today, the determination of antibodies against TORCH parameters are an essential part of pre-, peri- and postnatal care. The diagnostic procedure depends on the patient history, special risk factors and national regulations. The tests are generally performed during the first trimester of pregnancy, but they can also be carried out on the newborn. The initial investigation of antibodies against TORCH pathogens is aimed at determining the immune status of the mother to be able to differentiate between acute and past infections during the course of pregnancy. If there is no immunity against one of the TORCH pathogens, it is very important for the mother to avoid contact with known infection sources during pregnancy.

Product overview

Methode	Substrate	Application	Order number	Page
ELISA	Native whole antigen of <i>Toxoplasma gondii</i>	IgG/IgM ELISA: complete antigen spectrum; IgA ELISA: additional detection of IgA antibodies in ambiguous cases; avidity determination: exclusion of acute infection	EI 2410-9601 P EI 2410-9601 A/G/M EI 2410-9601-1 G	178 178 178
	Cell lysate (IgG) and glycoproteins (IgM) of rubella virus	IgG ELISA: complete antigen spectrum; IgM ELISA: highest specificity through the use of pathogen-specific glycoproteins; avidity determination: exclusion of acute infection	EI 2590-9601 G EI 2590-9601-1 G EI 2590-9601-2 M	179 179 179
	Cell lysate of cytomegalovirus	IgG/IgM ELISA: complete antigen spectrum; avidity determination: exclusion of acute infection	EI 2570-9601 G/M EI 2570-9601-1 G	178 178
	Cell lysate of HSV-1 and -2	IgG/IgM ELISA: screening test; IgA ELISA: additional determination of IgA antibodies in ambiguous cases	EI 2531-9601-1 A/G/M	178
	Type-specific glycoprotein C1 of HSV-1 or G2 of HSV-2	Differentiation between serotypes (HSV-1, -2)	EI 2531-9601-2 G/M EI 2532-9601-2 G/M	178 178
Blot	Separate antigen bands: <i>Toxoplasma gondii</i> , rubella virus, CMV, HSV	Multiplex detection of IgG/ IgM antibodies against different TORCH antigens	DN 2410-1601-4 G/M	173



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code q100 at www.euroimmun.com

Special infection diagnostics


CSF diagnostics · TORCH · Tropical infections



For more information on this subject scan the QR code or enter the Quick Link code q045 at www.euroimmun.com

Tropical infections and emerging diseases

- **Clinical information:** The majority of tropical diseases are caused by pathogens that are transmitted by blood-sucking insects, particularly mosquitoes. Emerging diseases are infections in humans that have been on the rise over the past decades or which are likely to occur more often in the near future. These are generally febrile diseases with unspecific flu-like symptoms. In the course of the disease severe complications such as encephalitis, haemorrhaging or disorders of the kidneys or the respiratory tract can occur.
- **Diagnostics:** The diagnosis of tropical infections and emerging diseases is a particular challenge in countries in which these diseases have not previously occurred. Over the past years it has been observed that a number of new viruses (emerging or re-emerging viruses) and other pathogens have spread worldwide, introducing unknown diseases into previously unaffected regions. For rare parameters there are often no commercial diagnostic test systems available. Antibody analysis is useful for testing travellers after trips to endemic areas and for screening large population groups. EUROIMMUN offers a wide range of products for the determination of specific antibodies against many pathogens.



Product overview

Method	Substrate	Application	Order number	Page
ELISA	Dengue virus particle (type 2)	Monospecific detection of anti-dengue virus antibodies	EI 266b-9601 A/G/M	180
	Monoclonal mouse anti-dengue virus NS1 antibody	Early marker for acute dengue infections	EQ 266a-9601-1	182
	Highly purified TBE virus proteins (strain K23)	Quantification of specific anti-TBE virus antibodies in RU or Vienna units	EI 2661-9601 G/M EI 2661-9601-9 G	180 180
	Detergent-extracted glycoprotein E from West Nile virus	Quantification of specific anti-WNV antibodies	EI 2662-9601 G/M	180
	Recombinant viral structure protein from Chikungunya virus	Highly specific test for the diagnosis of Chikungunya fever	EI 293a-9601 G/M	182
	Mixture of recombinant N-proteins from Hantavirus strains HTNV, DOBV, PUUUV, ANDV and SNV	Reliable diagnosis of hantavirus infections from European, Asian and American endemic areas	EI 278h-9601-1 G/M EI 278h-9601-2 G/M	181 181
Blot	Recombinant N-proteins from strains HTNV, DOBV, PUUUV, SEOV, SNV and ANDV	All hantavirus antigens for European, Asian and American endemic areas	DN 278h-1601-1 G/M DN 278h-1601-2 G/M	173 173
IFT*	Flavivirus: TBE virus, WNV, JEV, yellow fever virus, dengue virus types 1-4	Serological diagnosis of flavivirus infections; differential diagnostics of cross reactions	FI 2661-####-1 G/M FI 2661-####-2 G/M FI 2661-####-3 G/M	188 189 189
	Bunyavirus: hantavirus (HTNV, PUUUV, DOBV, SEOV, SAAV, SNV, ANDV); sandfly fever virus (SFSV, SFNV, TOSV, CYPV); RVFV; CCHFV	Worldwide largest range of CE-certified antibody tests for the diagnosis of infections with the most important bunyaviruses	FI 278h-####-2 G/M FI 278m-####-3 G/M FI 277a-####-1 G/M FI 279a-####-2 G/M FI 280a-#### G/M	191 191 190 192 192
	Arbovirus Fever Mosaic: Chikungunya virus, dengue virus, JEV	For differential diagnosis of arbovirus infections, in particular DENV and CHIKV infections	FI 293a-####-1 G/M	193

*) Further parameters available: Leishmania donovani, Schistosoma mansoni, MERS CoV, Sindbis virus, Plasmodia.



To view all EUROIMMUN products for this subject scan the QR code or enter the Quick Link code q102 at www.euroimmun.com



Products for infectious serology

Infectious serology

Format

- 1601: 16 single test strips
- 1208: 12 microplate strips with 8 wells each
- 9601: 96 individual break-apart wells (12 microplate strips, 8 wells each)
- 1003: 10 slides with 3 fields each
- 1005: 10 slides with 5 fields each
- 2005: 20 slides with 5 fields each
- 1010: 10 slides with 10 fields each
- 1050: 10 slides with 50 fields each
- 1001: 10 slides to be incubated with 1 patient serum each
- 1002: 10 slides to be incubated with 2 patient sera each

EI **2132 - 9601** **-2** **G**

Product code

Immunoglobulin class

- A: IgA
- G: IgG
- M: IgM
- O: IgGM
- P: Polyclonal (IgAGM)
- X: Low-avid ab of class IgG
- H: High-avid ab of class IgG

Product classification

- CI: Control for EUROIMMUN IIFT (infectious serology) page 164
- CL: Control for EUROLINE (infectious serology) page 171
- CW: Control for Westernblot/EUROLINE-WB (infectious serology) page 172
- DN: Test system EUROLINE (infectious serology) page 173
- DY: Test system Westernblot/EUROLINE-WB (infectious serology) page 174
- EI: Test system microplate ELISA (infectious serology) page 176
- EQ: Test system microplate ELISA (infectious diseases, antigen determination) page 182
- CK: ELISA control (infectious serology) page 183
- FI: Test system indirect immunofluorescence (infectious serology) page 184
- FK: Single slides indirect immunofluorescence (infectious serology) page 184

For product orders the amount, product code and test name are required. **Test kits** comprise all reagents needed to perform the serological investigation. For diagnostics in indirect immunofluorescence, for example, these include slides, FITC-labelled antibodies against human immunoglobulin, positive and negative control sera (not available for some products) as well as embedding medium, cover glasses, sachets of PBS and Tween 20. EUROSORB for the determination of IgM class antibodies and sample buffer 3 (for anti-borrelia IIFT only) are not included in the immunofluorescence test systems.

Substrates consisting of cell cultures and tissues which do not appear in this catalogue can be made to specification. In addition, BIOCHIP mosaics can be produced according to individual requirements. Apart from the customary package sizes and slide formats, special sizes are available as well. Quotations can be provided upon request.

Controls for EUROIMMUN IIFT: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CI 2050-0101 A	antibodies against <i>Bordetella pertussis</i> IgA positive control	IgA	0.1 ml
CI 2050-0101 G	antibodies against <i>Bordetella pertussis</i> IgG positive control	IgG	0.1 ml
CI 2050-0101 M	antibodies against <i>Bordetella pertussis</i> IgM positive control	IgM	0.1 ml
CI 2050-0101 Z	<i>Bordetella pertussis/parapertussis</i> negative control	IgA, IgG, IgM	0.1 ml
CI 2055-0101 A	antibodies against <i>Bordetella parapertussis</i> IgA positive control	IgA	0.1 ml
CI 2055-0101 G	antibodies against <i>Bordetella parapertussis</i> IgG positive control	IgG	0.1 ml
CI 2055-0101 M	antibodies against <i>Bordetella parapertussis</i> IgM positive control	IgM	0.1 ml
CI 2055-0101 Z	<i>Bordetella parapertussis</i> negative control	IgA, IgG, IgM	0.1 ml
CI 2080-0101 A	antibodies against <i>Helicobacter pylori</i> IgA positive control	IgA	0.1 ml
CI 2080-0101 G	antibodies against <i>Helicobacter pylori</i> IgG positive control	IgG	0.1 ml
CI 2080-0101 M	antibodies against <i>Helicobacter pylori</i> IgM positive control	IgM	0.1 ml
CI 2080-0101 Z	<i>Helicobacter pylori</i> negative control	IgA, IgG, IgM	0.1 ml
CI 2091-0101 A	antibodies against <i>Campylobacter jejuni</i> IgA positive control	IgA	0.1 ml
CI 2091-0101 G	antibodies against <i>Campylobacter jejuni</i> IgG positive control	IgG	0.1 ml
CI 2091-0101 Z	<i>Campylobacter jejuni/coli</i> negative control	IgA, IgG, IgM	0.1 ml
CI 2111-0101 G CI 2111-0102 G	antibodies against <i>Treponema pallidum</i> unspecific FTA IgG positive control	IgG	0.1 ml 0.25 ml
CI 2111-0101 M CI 2111-0102 M	antibodies against <i>Treponema pallidum</i> unspecific FTA IgM positive control	IgM	0.1 ml 0.25 ml
CI 2111-0101 Z	<i>Treponema pallidum</i> FTA negative control	IgA, IgG, IgM	0.1 ml
CI 2111-0150-1 G	antibodies against <i>Treponema pallidum</i> IgG positive control for FTA absorption	IgG	50 µl serum concentrate
CI 2131-0101 G CI 2131-0102 G CI 2131-0105 G	antibodies against <i>Borrelia afzelii/B. burgdorferi/B. garinii/VlsE</i> IgG positive control	IgG	0.1 ml 0.25 ml 0.5 ml
CI 2131-0101 M CI 2131-0102 M CI 2131-0105 M	antibodies against <i>Borrelia afzelii/B. burgdorferi/B. garinii/OspC</i> IgM positive control	IgM	0.1 ml 0.25 ml 0.5 ml
CI 2131-0101 Z CI 2131-0102 Z CI 2131-0105 Z	<i>Borrelia afzelii/B. burgdorferi/B. garinii</i> negative control	IgA, IgG, IgM	0.1 ml 0.25 ml 0.5 ml
CI 2140-0101 Z CI 2140-0102 Z	<i>Listeria monocytogenes</i> negative control	IgA, IgG, IgM	0.1 ml 0.25 ml
CI 2141-0101 G CI 2141-0102 G	antibodies against <i>Listeria monocytogenes 1/2a</i> IgG positive control	IgG	0.1 ml 0.25 ml
CI 2141-0101 M CI 2141-0102 M	antibodies against <i>Listeria monocytogenes 1/2a</i> IgM positive control	IgM	0.1 ml 0.25 ml

Controls for EUROIMMUN IIFT: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CI 2144-0101 G	antibodies against Listeria monocytogenes 4b IgG positive control	IgG	0.1 ml
CI 2150-0101 P CI 2150-0102 P	antibodies against Legionella pneumophila serotypes 1 or 4 IgAGM positive control	IgAGM	0.1 ml 0.25 ml
CI 2150-0101-4 G CI 2150-0102-4 G	antibodies against Legionella pneumophila mixture 1-2-3-4-5-6-7, mixture 8-9-10-11-12-13-14, mixture L. non-pneumophila 6 sp IgG positive control	IgG	0.1 ml 0.25 ml
CI 2150-0101-4 P	antibodies against Legionella pneumophila mixture 1-2-3-4-5-6-7, mixture 8-9-10-11-12-13-14, mixture L. non-pneumophila 6 sp IgAGM positive control	IgAGM	0.1 ml
CI 2151-0101 G	antibodies against Legionella pneumophila serotype 1 IgG positive control	IgG	0.1 ml
CI 2151-0101 P	antibodies against Legionella pneumophila serotype 1 IgAGM positive control	IgAGM	0.1 ml
CI 2151-0101 Z CI 2151-0102 Z	Legionella pneumophila/non-pneumophila negative control	IgA, IgG, IgM	0.1 ml 0.25 ml
CI 215b-0101 P	antibodies against Legionella pneumophila mixture 1-4-6-8 IgAGM positive control	IgAGM	0.1 ml
CI 215d-0101 P	antibodies against Legionella pneumophila mixture 2-3-5-7 IgAGM positive control	IgAGM	0.1 ml
CI 215f-0101 P	antibodies against Legionella pneumophila mixture 9-11-13 IgAGM positive control	IgAGM	0.1 ml
CI 215h-0101 P CI 215h-0102 P	antibodies against Legionella pneumophila mixture 10-12-14 IgAGM positive control	IgAGM	0.1 ml 0.25 ml
CI 2165-0101 P CI 2165-0102 P	antibodies against Legionella jordanis IgAGM positive control	IgAGM	0.1 ml 0.25 ml
CI 2168-0101 G	antibodies against Legionella longbeachae IgG positive control	IgG	0.1 ml
CI 2168-0101 P	antibodies against Legionella longbeachae IgAGM positive control	IgAGM	0.1 ml
CI 2191-0101 A	antibodies against Chlamydia trachomatis IgA positive control	IgA	0.1 ml
CI 2191-0101 G	antibodies against Chlamydia trachomatis IgG positive control	IgG	0.1 ml
CI 2191-0101 M	antibodies against Chlamydia trachomatis IgM positive control	IgM	0.1 ml
CI 2191-0101-1 Z	Chlamydia spp. negative control	IgA, IgG, IgM	0.1 ml
CI 2192-0101 A	antibodies against Chlamydia pneumoniae IgA positive control	IgA	0.1 ml
CI 2192-0101 G	antibodies against Chlamydia pneumoniae IgG positive control	IgG	0.1 ml
CI 2192-0101 M	antibodies against Chlamydia pneumoniae IgM positive control	IgM	0.1 ml
CI 2193-0101 A	antibodies against Chlamydia psittaci IgA positive control	IgA	0.1 ml
CI 2193-0101 G	antibodies against Chlamydia psittaci IgG positive control	IgG	0.1 ml
CI 2193-0101 M	antibodies against Chlamydia psittaci IgM positive control	IgM	0.1 ml
CI 219b-0101 G CI 219b-0102 G	antibodies against Bartonella henselae IgG positive control	IgG	0.1 ml 0.25 ml
CI 219b-0101 M CI 219b-0102 M	antibodies against Bartonella henselae IgM positive control	IgM	0.1 ml 0.25 ml

Controls for EUROIMMUN IIFT: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CI 219b-0101 Z CI 219b-0102 Z	Bartonella henselae/quintana negative control	IgA, IgG, IgM	0.1 ml 0.25 ml
CI 219d-0101 G	antibodies against Bartonella quintana IgG positive control	IgG	0.1 ml
CI 219d-0101 M	antibodies against Bartonella quintana IgM positive control	IgM	0.1 ml
CI 2201-0101 G	antibodies against Mycoplasma hominis IgG positive control	IgG	0.1 ml
CI 2201-0101 Z	Mycoplasma hominis/pneumoniae and Ureaplasma urealyticum negative control	IgA, IgG, IgM	0.1 ml
CI 2202-0101 G	antibodies against Mycoplasma pneumoniae IgG positive control	IgG	0.1 ml
CI 2202-0101 M	antibodies against Mycoplasma pneumoniae IgM positive control	IgM	0.1 ml
CI 2205-0101 G	antibodies against Ureaplasma urealyticum IgG positive control	IgG	0.1 ml
CI 2231-0101 A	antibodies against Leishmania donovani IgA positive control	IgA	0.1 ml
CI 2231-0101 G	antibodies against Leishmania donovani IgG positive control	IgG	0.1 ml
CI 2231-0101 Z	Leishmania donovani negative control	IgA, IgG, IgM	0.1 ml
CI 2300-0101 G CI 2300-0105 G	antibodies against Schistosoma mansoni IgG positive control	IgG	0.1 ml 0.5 ml
CI 2300-0101 M	antibodies against Schistosoma mansoni IgM positive control	IgM	0.1 ml
CI 2300-0101 Z CI 2300-0105 Z	Schistosoma mansoni negative control	IgA, IgG, IgM	0.1 ml 0.5 ml
CI 2320-0101 A	antibodies against Echinococcus granulosus IgA positive control	IgA	0.1 ml
CI 2320-0101 G	antibodies against Echinococcus granulosus IgG positive control	IgG	0.1 ml
CI 2320-0101 Z	Echinococcus granulosus negative control	IgA, IgG, IgM	0.1 ml
CI 2410-0101 G CI 2410-0102 G	antibodies against Toxoplasma gondii IgG positive control	IgG	0.1 ml 0.25 ml
CI 2410-0101 H	high-avid antibodies against Toxoplasma gondii IgG positive control	IgG	0.1 ml
CI 2410-0101 M CI 2410-0102 M	antibodies against Toxoplasma gondii IgM positive control	IgM	0.1 ml 0.25 ml
CI 2410-0101 X	low-avid antibodies against Toxoplasma gondii IgG positive control	avidity test	0.1 ml
CI 2410-0101 Z CI 2410-0102 Z	Toxoplasma gondii negative control	IgG, IgM	0.1 ml 0.25 ml
CI 2531-0101 G	antibodies against Herpes simplex virus 1 (HSV-1) IgG positive control	IgG	0.1 ml
CI 2531-0101 M	antibodies against Herpes simplex virus 1 (HSV-1) IgM positive control	IgM	0.1 ml
CI 2531-0101 Z	HSV-1/HSV-2 negative control	IgA, IgG, IgM	0.1 ml
CI 2532-0101 G	antibodies against Herpes simplex virus 2 (HSV-2) IgG positive control	IgG	0.1 ml

Infectious serology

Controls for EUROIMMUN IIFT: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CI 2532-0101 M	antibodies against Herpes simplex virus 2 (HSV-2) IgM positive control	IgM	0.1 ml
CI 2536-0101 G CI 2536-0102 G	antibodies against human herpes virus 6 (HHV-6) IgG positive control	IgG	0.1 ml 0.25 ml
CI 2536-0101 M CI 2536-0102 M	antibodies against human herpes virus 6 (HHV-6) IgM positive control	IgM	0.1 ml 0.25 ml
CI 2536-0101 Z CI 2536-0102 Z	human herpes virus 6 (HHV-6) negative control	IgG, IgM	0.1 ml 0.25 ml
CI 2570-0101 A	antibodies against Cytomegalovirus (CMV) IgA positive control	IgA	0.1 ml
CI 2570-0101 G	antibodies against Cytomegalovirus (CMV) IgG positive control	IgG	0.1 ml
CI 2570-0101 H	high-avid antibodies against Cytomegalovirus (CMV) IgG positive control	IgG	0.1 ml
CI 2570-0101 M	antibodies against Cytomegalovirus (CMV) IgM positive control	IgM	0.1 ml
CI 2570-0101 X	low-avid antibodies against Cytomegalovirus (CMV) IgG positive control	avidity test	0.1 ml
CI 2570-0101 Z	Cytomegalovirus (CMV) negative control	IgA, IgG, IgM	0.1 ml
CI 2590-0101 G	antibodies against Rubella virus IgG positive control	IgG	0.1 ml
CI 2590-0101 H	high-avid antibodies against Rubella virus IgG positive control	IgG	0.1 ml
CI 2590-0101 X	low-avid antibodies against Rubella virus IgG positive control	avidity test	0.1 ml
CI 2590-0101 Z	Rubella virus negative control	IgG	0.1 ml
CI 2601-0101 Z	MERS-CoV, SARS-CoV negative control	IgA, IgG, IgM	0.1 ml
CI 2610-0101 G	antibodies against Measles virus IgG positive control	IgG	0.1 ml
CI 2610-0101 M	antibodies against Measles virus IgM positive control	IgM	0.1 ml
CI 2610-0101 Z	Measles virus negative control	IgG, IgM	0.1 ml
CI 2630-0101 G	antibodies against Mumps virus IgG positive control	IgG	0.1 ml
CI 2630-0101 M	antibodies against Mumps virus IgM positive control	IgM	0.1 ml
CI 2630-0101 Z	Mumps virus negative control	IgG, IgM	0.1 ml
CI 2650-0101 A CI 2650-0102 A	antibodies against Varicella zoster virus (VZV) IgA positive control	IgA	0.1 ml 0.25 ml
CI 2650-0101 G CI 2650-0102 G	antibodies against Varicella zoster virus (VZV) IgG positive control	IgG	0.1 ml 0.25 ml
CI 2650-0101 H	high-avid antibodies against Varicella zoster virus (VZV) IgG positive control	IgG	0.1 ml
CI 2650-0101 M CI 2650-0102 M	antibodies against Varicella zoster virus (VZV) IgM positive control	IgM	0.1 ml 0.25 ml
CI 2650-0101 X	low-avid antibodies against Varicella zoster virus (VZV) IgG positive control	avidity test	0.1 ml

Controls for EUROIMMUN IIFT: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CI 2650-0101 Z	Varicella zoster virus (VZV) negative control	IgA, IgG, IgM	0.1 ml 0.25 ml
CI 2650-0102 Z			
CI 2661-0101 G	antibodies against TBE virus IgG positive control	IgG	0.1 ml
CI 2661-0101 M	antibodies against TBE virus IgM positive control	IgM	0.1 ml
CI 2661-0101 Z	TBE virus negative control	IgA, IgG, IgM	0.1 ml
CI 2661-0101-1 G	antibodies against Flaviviruses IgG positive control	IgG	0.1 ml
CI 2661-0101-1 Z	Flaviviruses negative control	IgA, IgG, IgM	0.1 ml
CI 2662-0101 G	antibodies against West Nile virus (WNV) IgG positive control	IgG	0.1 ml
CI 2662-0101 M	antibodies against West Nile virus (WNV) IgM positive control	IgM	0.1 ml
CI 2662-0101 X	low-avid antibodies against West Nile virus (WNV) IgG positive control	avidity test	0.1 ml
CI 2662-0101 Z	West Nile virus (WNV) negative control	IgA, IgG, IgM	0.1 ml
CI 2663-0101 G	antibodies against Japanese encephalitis virus (JEV) IgG positive control	IgG	0.1 ml
CI 2663-0101 M	antibodies against Japanese encephalitis virus (JEV) IgM positive control	IgM	0.1 ml
CI 2663-0101 Z	antibodies against Japanese encephalitis virus (JEV) negative control	IgA, IgG, IgM	0.1 ml
CI 2665-0101 G	antibodies against Yellow fever virus (YFV) IgG positive control	IgG	0.1 ml
CI 2665-0101 M	antibodies against Yellow fever virus (YFV) IgM positive control	IgM	0.1 ml
CI 2665-0101 Z	Yellow fever virus (YFV) negative control	IgA, IgG, IgM	0.1 ml
CI 266a-0101 G	antibodies against Dengue virus (DENV) IgG positive control	IgG	0.1 ml
CI 266a-0101 M	antibodies against Dengue virus (DENV) IgM positive control	IgM	0.1 ml
CI 266a-0101 Z	Dengue virus (DENV) negative control	IgA, IgG, IgM	0.1 ml
CI 2670-0101 A	antibodies against Respiratory syncytial virus (RSV) IgA positive control	IgA	0.1 ml
CI 2670-0101 G	antibodies against Respiratory syncytial virus (RSV) IgG positive control	IgG	0.1 ml
CI 2670-0101 M	antibodies against Respiratory syncytial virus (RSV) IgM positive control	IgM	0.1 ml
CI 2670-0101 Z	Respiratory syncytial virus (RSV) negative control	IgA, IgG, IgM	0.1 ml
CI 2680-0101 A	antibodies against Adenovirus IgA positive control	IgA	0.1 ml
CI 2680-0101 G	antibodies against Adenovirus IgG positive control	IgG	0.1 ml
CI 2680-0101 M	antibodies against Adenovirus IgM positive control	IgM	0.1 ml

Infectious serology

Controls for EUROIMMUN IIFT: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CI 2680-0101 Z	Adenovirus negative control	IgA, IgG, IgM	0.1 ml
CI 2691-0101 A	antibodies against Influenza virus type A IgA positive control	IgA	0.1 ml
CI 2691-0101 G	antibodies against Influenza virus type A IgG positive control	IgG	0.1 ml
CI 2691-0101 M	antibodies against Influenza virus type A IgM positive control	IgM	0.1 ml
CI 2691-0101 Z	Influenza virus type A/B negative control	IgA, IgG, IgM	0.1 ml
CI 2692-0101 A	antibodies against Influenza virus type B IgA positive control	IgA	0.1 ml
CI 2692-0101 G	antibodies against Influenza virus type B IgG positive control	IgG	0.1 ml
CI 2692-0101 M	antibodies against Influenza virus type B IgM positive control	IgM	0.1 ml
CI 2720-0101 A	antibodies against Parainfluenza virus types 1 - 4 IgA positive control	IgA	0.1 ml
CI 2720-0101 G	antibodies against Parainfluenza virus types 1 - 4 IgG positive control	IgG	0.1 ml
CI 2720-0101 M	antibodies against Parainfluenza virus types 1 - 4 IgM positive control	IgM	0.1 ml
CI 2720-0101 Z	Parainfluenza virus negative control	IgA, IgG, IgM	0.1 ml
CI 2730-0101 A CI 2730-0102 A	antibodies against Coxsackie virus IgA positive control	IgA	0.1 ml 0.25 ml
CI 2730-0101 G CI 2730-0102 G	antibodies against Coxsackie virus IgG positive control	IgG	0.1 ml 0.25 ml
CI 2730-0101 M CI 2730-0102 M	antibodies against Coxsackie virus IgM positive control	IgM	0.1 ml 0.25 ml
CI 2730-0101 Z CI 2730-0102 Z	Coxsackie virus negative control	IgA, IgG, IgM	0.1 ml 0.25 ml
CI 275a-0101 G CI 275a-0102 G	antibodies against Echo virus IgG positive control	IgG	0.1 ml 0.25 ml
CI 275a-0101 M CI 275a-0102 M	antibodies against Echo virus IgM positive control	IgM	0.1 ml 0.25 ml
CI 275a-0101 Z CI 275a-0102 Z	Echo virus negative control	IgA, IgG, IgM	0.1 ml 0.25 ml
CI 277a-0101-1 G	antibodies against Sandfly fever virus IgG positive control	IgG	0.1 ml
CI 277a-0101-1 M	antibodies against Sandfly fever virus IgM positive control	IgM	0.1 ml
CI 277a-0101-1 Z	Sandfly fever virus negative control	IgA, IgG, IgM	0.1 ml
CI 278h-0101-1 G	antibodies against Hantavirus IgG positive control	IgG	0.1 ml
CI 278h-0101-1 M	antibodies against Hantavirus IgM positive control	IgM	0.1 ml
CI 278h-0101-1 Z	Hantavirus negative control	IgA, IgG, IgM	0.1 ml
CI 2791-0101 A	antibodies against Epstein-Barr virus capsid antigen (EBV-CA) IgA positive control	IgA	0.1 ml

Controls for EUROIMMUN IIFT: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CI 2791-0101 G	antibodies against Epstein-Barr virus capsid antigen (EBV-CA) IgG positive control	IgG	0.1 ml
CI 2791-0101 H	high-avid antibodies against Epstein-Barr virus capsid antigen (EBV-CA) IgG positive control	IgG	0.1 ml
CI 2791-0101 M	antibodies against Epstein-Barr virus capsid antigen (EBV-CA) IgM positive control	IgM	0.1 ml
CI 2791-0101 X	low-avid antibodies against Epstein-Barr virus (EBV-CA) IgG positive control	avidity test	0.1 ml
CI 2791-0101 Z	Epstein-Barr virus (EBV) negative control	IgA, IgG, IgM	0.1 ml
CI 2793-0101 C	antibodies against Epstein-Barr virus nuclear antigen (EBNA) complement-binding, positive control	IgG	0.1 ml
CI 2795-0101 A	antibodies against Epstein-Barr virus early antigen (EBV-EA) IgA positive control	IgA	0.1 ml
CI 2795-0101 G	antibodies against Epstein-Barr virus early antigen (EBV-EA) IgG positive control	IgG	0.1 ml
CI 2795-0101 H	high-avid antibodies against Epstein-Barr virus early antigen (EBV-EA) IgG positive control	IgG	0.1 ml
CI 2795-0101 X	low-avid antibodies against Epstein-Barr virus early antigen (EBV-EA) IgG positive control	avidity test	0.1 ml
CI 279a-0101 G	antibodies against Crimean Congo fever virus IgG positive control	IgG	0.1 ml
CI 279a-0101 M	antibodies against Crimean Congo fever virus IgM positive control	IgM	0.1 ml
CI 279a-0101 Z	Crimean Congo fever virus negative control	IgA, IgG, IgM	0.1 ml
CI 280a-0101 Z	Rift Valley fever virus (RVFV) negative control	IgA, IgG, IgM	0.1 ml
CI 2861-0101 A CI 2861-0102 A	antibodies against Candida albicans IgA positive control	IgA	0.1 ml 0.25 ml
CI 2861-0101 G	antibodies against Candida albicans IgG positive control	IgG	0.1 ml
CI 2861-0101 M	antibodies against Candida albicans IgM positive control	IgM	0.1 ml
CI 2861-0101 Z	Candida albicans negative control	IgA, IgG, IgM	0.1 ml
CI 291a-0101 Z * CI 291a-0102 Z *	Sindbis virus negative control	IgA, IgG, IgM	0.1 ml 0.25 ml
CI 293a-0101 G CI 293a-0102 G	antibodies against Chikungunya virus (CHIKV) IgG positive control	IgG	0.1 ml 0.25 ml
CI 293a-0101 M	antibodies against Chikungunya virus (CHIKV) IgM positive control	IgM	0.1 ml
CI 293a-0101 Z CI 293a-0102 Z	Chikungunya virus (CHIKV) negative control	IgA, IgG, IgM	0.1 ml 0.25 ml

*) Currently not available as IVD in the European Union.
Further control sera for infectious serology upon request.

Infectious serology

Controls for EUROLINE: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CW 2000-0001 ZA	negative control for infectious serology blot systems (IgA)	IgA	0.1 ml
CW 2000-0001 ZG	negative control for infectious serology blot systems (IgG)	IgG	0.1 ml
CW 2000-0001 ZM	negative control for infectious serology blot systems (IgM)	IgM	0.1 ml
CL 2050-0107 G	positive control serum: IgG, human, 50x concentrated for Bordetella pertussis	IgG	0.1 ml for EUROBlotOne
CL 2131-0107 G	positive control serum: IgG, human, 50x concentrated for Borrelia	IgG	0.1 ml for EUROBlotOne
CL 2131-0107 M	positive control serum: IgM, human, 50x concentrated for Borrelia	IgM	0.1 ml for EUROBlotOne
CL 2410-0107-4 G *	positive control serum: IgG, human, 50x concentrated for T.O.R.C.H. Profile	IgG	0.1 ml for EUROBlotOne
CL 2410-0107-4 M *	positive control serum: IgM, human, 50x concentrated for T.O.R.C.H. Profile	IgM	0.1 ml for EUROBlotOne
CL 2790-0107-12 G	positive control serum: IgG, human, 50x concentrated for EBV-Profil 2 G	IgG	0.1 ml for EUROBlotOne
CL 2790-0107-12 M	positive control serum: IgM, human, 50x concentrated for EBV-Profil 2 M	IgM	0.1 ml for EUROBlotOne

*) Currently not available as IVD in the European Union.

Controls for Westernblot/EUROLINE-WB: Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CW 2000-0001 ZA	negative control for infectious serology blot systems (IgA)	IgA	0.1 ml
CW 2000-0001 ZG	negative control for infectious serology blot systems (IgG)	IgG	0.1 ml
CW 2000-0001 ZM	negative control for infectious serology blot systems (IgM)	IgM	0.1 ml
CW 2080-5001 A	antibodies against Helicobacter pylori IgA positive control	IgA	0.1 ml
CW 2080-5001 G	antibodies against Helicobacter pylori IgG positive control	IgG	0.1 ml
CW 2111-5001 G	antibodies against Treponema pallidum IgG positive control	IgG	0.1 ml
CW 2111-5001 M	antibodies against Treponema pallidum IgM positive control	IgM	0.1 ml
CW 2131-5001 G	antibodies against Borrelia afzelii IgG positive control (Westernblot/EUROLINE-WB)	IgG	0.1 ml
CW 2131-5001 M	antibodies against Borrelia afzelii IgM positive control (Westernblot/EUROLINE-WB)	IgM	0.1 ml
CW 2132-5001 G	antibodies against Borrelia burgdorferi IgG positive control	IgG	0.1 ml
CW 2132-5001 M	antibodies against Borrelia burgdorferi IgM positive control	IgM	0.1 ml
CW 2134-5001 G	antibodies against Borrelia garinii IgG positive control	IgG	0.1 ml
CW 2134-5001 M	antibodies against Borrelia garinii IgM positive control	IgM	0.1 ml
CW 2173-5001 A	antibodies against Yersinia enterocolitica IgA positive control (for diagnosing various forms of arthritis)	IgA	0.1 ml
CW 2173-5001 G	antibodies against Yersinia enterocolitica IgG positive control (for diagnosing various forms of arthritis)	IgG	0.1 ml
CW 2531-5001 G	antibodies against Herpes simplex virus (HSV) IgG positive control	IgG	0.1 ml
CW 2790-5001 G	antibodies against Epstein-Barr virus (EBV) IgG positive control	IgG	0.1 ml
CW 2790-5001 M	antibodies against Epstein-Barr virus (EBV) IgM positive control	IgM	0.1 ml

Infectious serology

EUROLINE for Infectious Serology (Test Systems)

Order No.	Antibodies against	Ig Class	Substrate	Format
DL 0160-1601 G	EUROLINE validation	IgG	membrane strip with antigens (EUROLINE)	16 strips
DN 2050-1601 A DN 2050-24001 A	Bordetella pertussis (FHA, PT, ACT separately)	IgA	membrane strip with antigens (EUROLINE)	16 strips 240 strips
DN 2050-1601 G DN 2050-24001 G	Bordetella pertussis (FHA, PT, ACT separately)	IgG	membrane strip with antigens (EUROLINE)	16 strips 240 strips
DN 2131-3201 G DN 2131-24001 G	EUROLINE Borrelia-RN-AT (p18, p19, p20, p21, p58, OspC (p25), p39, p83, LBb, LBa, VlsE Bg, VlsE Bb, VlsE Ba separately)	IgG	membrane strip with antigens (EUROLINE)	32 strips 240 strips
DN 2131-3201 M DN 2131-24001 M	EUROLINE Borrelia-RN-AT (OspC Bg native, OspC Bb native, OspC Ba native, p39, VlsE Bb separately)	IgM	membrane strip with antigens (EUROLINE)	32 strips 240 strips
DN 2131-3201-2 M DN 2131-24001-2 M	EUROLINE Borrelia-RN-AT-adv (OspC-adv Bsp, OspC-adv Bg, OspC-adv Bb, OspC-adv Ba, p39, VlsE Bb separately)	IgM	membrane strip with antigens (EUROLINE)	32 strips 240 strips
DN 2410-1601-4 G * DN 2410-6401-4 G *	"TO.R.C.H. Profile" (Toxoplasma gondii, Rubella virus, CMV, HSV-1, HSV-2 separately)	IgG	membrane strip with antigens (EUROLINE)	16 strips 64 strips
DN 2410-1601-4 M * DN 2410-6401-4 M *	"TO.R.C.H. Profile" (Toxoplasma gondii, ROP1, Rubella virus, CMV, HSV-1, HSV-2 separately)	IgM	membrane strip with antigens (EUROLINE)	16 strips 64 strips
DN 2410-1601-11 G DN 2410-6401-11 G	"TO.R.C.H. 10" (Toxoplasma gondii, Rubella virus, CMV, HSV-1, HSV-2, Bordetella pertussis, Chlamydia trachomatis, Parvo virus B19, Treponema pallidum, VZV separately)	IgG	membrane strip with antigens (EUROLINE)	16 strips 64 strips
DN 2580-1601 G	Parvovirus B19 (VP1, VLP, VP2, NS1 separately)	IgG	membrane strip with antigens (EUROLINE)	16 strips
DN 2580-1601 M	Parvovirus B19 (VP1, VLP, VP2, NS1 separately)	IgM	membrane strip with antigens (EUROLINE)	16 strips
DN 278h-1601-1 G	Hantavirus Profile 1 (PUUV, DOBV, HTNV separately)	IgG	membrane strip with antigens (EUROLINE)	16 strips
DN 278h-1601-1 M	Hantavirus Profile 1 (PUUV, DOBV, HTNV separately)	IgM	membrane strip with antigens (EUROLINE)	16 strips
DN 278h-1601-2 G	Hantavirus Profile GLOBAL (PUUV, DOBV, HTNV, SEOV, SNV, ANDV separately)	IgG	membrane strip with antigens (EUROLINE)	16 strips
DN 278h-1601-2 M	Hantavirus Profile GLOBAL (PUUV, DOBV, HTNV, SEOV, SNV, ANDV separately)	IgM	membrane strip with antigens (EUROLINE)	16 strips
DN 2790-1601-2 G DN 2790-6401-2 G	EBV Profile 2 (VCA gp125, VCA p19, EBNA-1, p22, EA-D separately)	IgG	membrane strip with antigens (EUROLINE)	16 strips 64 strips
DN 2790-1601-2 M DN 2790-6401-2 M	EBV Profile 2 (VCA gp125, VCA p19, EBNA-1, p22, EA-D separately)	IgM	membrane strip with antigens (EUROLINE)	16 strips 64 strips

*) Currently not available as IVD in the European Union.

Westernblot/EUROLINE-WB for Infectious Serology (Test Systems)

Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Format
DY 2080-1601-1 A DY 2080-3001-1 A	EUROLINE-WB <i>Helicobacter pylori</i>	whole antigen of <i>H. pylori</i> , plus recombinant VacA and CagA antigen	IgA	16 strips 30 strips
DY 2080-1601-1 G DY 2080-3001-1 G	EUROLINE-WB <i>Helicobacter pylori</i>	whole antigen of <i>H. pylori</i> , plus recombinant VacA and CagA antigen	IgG	16 strips 30 strips
DY 2111-1601 G DY 2111-2401 G	<i>Treponema pallidum</i>	15 kDa, 17 kDa, 45 kDa (tmpA), 47 kDa	IgG	16 strips 24 strips
DY 2111-1601 M DY 2111-2401 M	<i>Treponema pallidum</i>	15 kDa, 17 kDa, 45 kDa (tmpA), 47 kDa	IgM	16 strips 24 strips
DY 2111-1601-1 G DY 2111-2401-1 G	EUROLINE-WB <i>Treponema pallidum</i> plus cardiolipin	15 kDa, 17 kDa, 45 kDa (tmpA) 47 kDa, plus purified cardiolipin	IgG	16 strips 24 strips
DY 2111-1601-1 M DY 2111-2401-1 M	EUROLINE-WB <i>Treponema pallidum</i> plus cardiolipin	15 kDa, 17 kDa, 45 kDa (tmpA) 47 kDa, plus purified cardiolipin	IgM	16 strips 24 strips
DY 2131-1601 G DY 2131-3001 G DY 2131-3201 G DY 2131-24001 G	<i>Borrelia afzelii</i>	whole antigen, SDS extract of <i>Borrelia afzelii</i>	IgG	16 strips 30 strips 32 strips 240 strips
DY 2131-1601 M DY 2131-3001 M DY 2131-3201 M DY 2131-24001 M	<i>Borrelia afzelii</i>	whole antigen, SDS extract of <i>Borrelia afzelii</i>	IgM	16 strips 30 strips 32 strips 240 strips
DY 2131-1601-1 G DY 2131-3001-1 G DY 2131-24001-1 G	EUROLINE-WB <i>Borrelia</i>	whole antigen, SDS extract of <i>Borrelia afzelii</i> plus VlsE	IgG	16 strips 30 strips 240 strips
DY 2131-1601-1 M DY 2131-3001-1 M DY 2131-24001-1 M	EUROLINE-WB <i>Borrelia</i>	whole antigen, SDS extract of <i>Borrelia afzelii</i> plus VlsE	IgM	16 strips 30 strips 240 strips
DY 2132-1601 G DY 2132-3001 G DY 2132-3201 G DY 2132-24001 G	<i>Borrelia burgdorferi</i>	whole antigen, SDS extract of <i>Borrelia burgdorferi</i> sensu stricto	IgG	16 strips 30 strips 32 strips 240 strips
DY 2132-1601 M DY 2132-3001 M DY 2132-3201 M DY 2132-24001 M	<i>Borrelia burgdorferi</i>	whole antigen, SDS extract of <i>Borrelia burgdorferi</i> sensu stricto	IgM	16 strips 30 strips 32 strips 240 strips
DY 2134-1601 G DY 2134-3001 G DY 2134-3201 G DY 2134-24001 G	<i>Borrelia garinii</i>	whole antigen, SDS extract of <i>Borrelia garinii</i>	IgG	16 strips 30 strips 32 strips 240 strips
DY 2134-1601 M DY 2134-3001 M DY 2134-3201 M DY 2134-24001 M	<i>Borrelia garinii</i>	whole antigen, SDS extract of <i>Borrelia garinii</i>	IgM	16 strips 30 strips 32 strips 240 strips
DY 2173-1601 A DY 2173-3001 A	<i>Yersinia enterocolitica</i> Detection of antibodies against virulence factors of the <i>Yersinia enterocolitica</i> pathogen in human serum (for diagnosing various forms of arthritis).	isolated virulence factors (release proteins, Yop) of <i>Yersinia enterocolitica</i>	IgA	16 strips 30 strips
DY 2173-1601 G DY 2173-3001 G	<i>Yersinia enterocolitica</i> Detection of antibodies against virulence factors of the <i>Yersinia enterocolitica</i> pathogen in human serum (for diagnosing various forms of arthritis).	isolated virulence factors (release proteins, Yop) of <i>Yersinia enterocolitica</i>	IgG	16 strips 30 strips
DY 2191-1601-1 A	EUROLINE-WB <i>Chlamydia trachomatis</i>	whole antigen, SDS extract of <i>Chlamydia trachomatis</i> plus MOMP antigen	IgA	16 strips
DY 2191-1601-1 G	EUROLINE-WB <i>Chlamydia trachomatis</i>	whole antigen, SDS extract of <i>Chlamydia trachomatis</i> plus MOMP antigen	IgG	16 strips
DY 2321-1601-1 G	<i>Echinococcus</i>	<i>Echinococcus multilocularis</i> and <i>Echinococcus granulosus</i>	IgG	16 strips

Infectious serology

Westernblot/EUROLINE-WB for Infectious Serology (Test Systems)

Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Format
DY 2531-1601-1 G DY 2531-2401-1 G	EUROLINE-WB Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2	whole antigen, SDS extract of HSV-1 plus purified gG2	IgG	16 strips 24 strips
DY 2531-1601-1 M DY 2531-2401-1 M	EUROLINE-WB Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2	whole antigen, SDS extract of HSV-1 plus purified gG2	IgM	16 strips 24 strips
DY 2570-1601 G * DY 2570-2401 G *	Cytomegalovirus (CMV)	whole antigen, SDS extract	IgG	16 strips 24 strips
DY 2570-1601 M * DY 2570-2401 M *	Cytomegalovirus (CMV)	whole antigen, SDS extract	IgM	16 strips 24 strips
DY 2590-2401 G	Rubella virus	whole antigen	IgG	24 strips
DY 2790-1601 G	Epstein-Barr virus (EBV)	whole antigen, SDS extract	IgG	16 strips
DY 2790-1601 M	Epstein-Barr virus (EBV)	whole antigen, SDS extract	IgM	16 strips

*) Currently not available as IVD in the European Union.

Microplate ELISA for Infectious Serology (Test Systems)					
Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Calibration	Format
EI 2040-9601 G	diphtheria toxoid	inactivated diphtheria toxin	IgG	0.01/0.1/1/2 IU/ml	96 x 01
EI 2050-9601 A	Bordetella pertussis toxin	highly purified Bordetella pertussis toxin	IgA	2/10/25/50 IU/ml	96 x 01
EI 2050-9601 G	Bordetella pertussis toxin	highly purified Bordetella pertussis toxin	IgG	5-200 IU/ml	96 x 01
EI 2050-9601 M	Bordetella pertussis incl. IgG/RF absorbent	inactivated Bordetella pertussis lysate	IgM	semi-quantitative	96 x 01
EI 2050-9601-3 A	Bordetella FHA	highly purified Bordetella pertussis filamentous haemagglutinin	IgA	2-50 IU/ml	96 x 01
EI 2050-9601-3 G	Bordetella FHA	highly purified Bordetella pertussis filamentous haemagglutinin	IgG	5-200 IU/ml	96 x 01
EI 2050-9601-4 G	Bordetella pertactin	native Bordetella pertussis pertactin	IgG	5/25/50/100 IU/ml	96 x 01
EI 2060-9601 G	tetanus toxoid	inactivated tetanus toxin	IgG	0,01/0,1/1/2/5 IU/ml	96 x 01
EI 2080-9601 A	Helicobacter pylori	bacterial lysate, strain "ATCC 43504"	IgA	semi-quantitative	96 x 01
EI 2080-9601 G	Helicobacter pylori	bacterial lysate, strain "ATCC 43504"	IgG	2/20/200 RU/ml	96 x 01
EI 2081-9601 A	Helicobacter pylori (CagA)	recombinant CagA, expression in E. coli	IgA	semi-quantitative	96 x 01
EI 2081-9601 G	Helicobacter pylori (CagA)	recombinant CagA, expression in E. coli	IgG	2/20/200 RU/ml	96 x 01
EI 2091-9601 A	Campylobacter jejuni	detergent extract, strain "ATCC 33291"	IgA	semi-quantitative	96 x 01
EI 2091-9601 G	Campylobacter jejuni	detergent extract, strain "ATCC 33291"	IgG	2/20/200 RU/ml	96 x 01
EI 2111-9601 G	Treponema pallidum	15 kDa, 17 kDa, 47 kDa, 42 kDa (TpmpA)	IgG	2/20/200 RU/ml	96 x 01
EI 2111-9601 M	Treponema pallidum incl. IgG/RF absorbent	15 kDa, 17 kDa, 47 kDa, 42 kDa (TpmpA)	IgM	semi-quantitative	96 x 01
EI 2111-9601 O	Treponema pallidum Screen ELISA	15 kDa, 17 kDa, 47 kDa, 42 kDa (TpmpA)	IgGM	2/20/200 RU/ml	96 x 01
EI 2111-9601-L G	Treponema pallidum antibody determination in CSF	15 kDa, 17 kDa, 47 kDa, 42 kDa (TpmpA)	IgG	5/25/50/100 U	96 x 01
EI 2132-9601 M	Borrelia incl. IgG/RF absorbent	whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii	IgM	2/20/200 RU/ml	96 x 01
EI 2132-9601-1 G	Borrelia burgdorferi VlsE	recombinant VlsE from Borrelia burgdorferi sensu stricto	IgG	2/20/200 RU/ml	96 x 01
EI 2132-9601-2 G	Borrelia plus VlsE	whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii plus recombinant VlsE from Borrelia burgdorferi sensu stricto	IgG	2/20/200 RU/ml	96 x 01
EI 2132-9601-5 G	Borrelia Select	mixture of specific recombinant Borrelia antigens incl. VlsE	IgG	2/20/200 RU/ml	96 x 01
EI 2132-9601-5 M	Borrelia Select	mixture of specific recombinant Borrelia antigens	IgM	2/20/200 RU/ml	96 x 01
EI 2132-9601-L G	Borrelia PLUS VlsE antibody determination in CSF	whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii PLUS recombinant VlsE from Borrelia burgdorferi sensu stricto	IgG	5-230 U	96 x 01

Infectious serology

Microplate ELISA for Infectious Serology (Test Systems)

Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Calibration	Format
EI 2132-9601-L M	Borrelia antibody determination in CSF	whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii	IgM	5/25/50/100/175 U	96 x 01
EI 2132-9601-24 O *	Lyme ELISA	recombinant VlsE from Borrelia burgdorferi sensu stricto and Borrelia OspC	IgGM	qualitative	96 x 01
EI 2150-9601 A	Legionella pneumophila	native, lipopolysaccharide (LPS) of serotypes 1 - 7	IgA	semi-quantitative	96 x 01
EI 2150-9601 G	Legionella pneumophila	native, lipopolysaccharide (LPS) of serotypes 1 - 7	IgG	2/20/200 RU/ml	96 x 01
EI 2150-9601 M	Legionella pneumophila incl. IgG/RF absorbent	native, lipopolysaccharide (LPS) of serotypes 1 - 7	IgM	semi-quantitative	96 x 01
EI 2173-9601 A	Yersinia enterocolitica	recombinant Yop D of Yersinia enterocolitica	IgA	semi-quantitative	96 x 01
EI 2173-9601 G	Yersinia enterocolitica	isolated virulence factors (release proteins, Yop) of Yersinia enterocolitica	IgG	2/20/200 RU/ml	96 x 01
EI 2189-9601 A	Brucella abortus	bacterial lysate, Brucella abortus strain "W99"	IgA	semi-quantitative	96 x 01
EI 2189-9601 G	Brucella abortus	bacterial lysate, Brucella abortus strain "W99"	IgG	2/20/200 RU/ml	96 x 01
EI 2189-9601 M	Brucella abortus incl. IgG/RF absorbent	bacterial lysate, Brucella abortus strain "W99"	IgM	semi-quantitative	96 x 01
EI 2190-9601 A	Chlamydia (C. pneumoniae/trachomatis Pool)	C. trach.: purified native MOMP antigen, serotype K C. pneum.: purified native antigens, strain "CWL-029"	IgA	semi-quantitative	96 x 01
EI 2190-9601 G	Chlamydia (C. pneumoniae/trachomatis Pool)	C. trach.: purified native MOMP antigen, serotype K C. pneum.: purified native antigens, strain "CWL-029"	IgG	2/20/200 RU/ml	96 x 01
EI 2190-9601 M	Chlamydia (C. pneumoniae/trachomatis Pool) incl. IgG/RF absorbent	C. trach.: purified native MOMP antigen, serotype K C. pneum.: purified native antigens, strain "CWL-029"	IgM	semi-quantitative	96 x 01
EI 2191-9601 A	Chlamydia trachomatis	purified native MOMP antigen, serotype K	IgA	semi-quantitative	96 x 01
EI 2191-9601 G	Chlamydia trachomatis	purified native MOMP antigen, serotype K	IgG	2/20/200 RU/ml	96 x 01
EI 2191-9601 M	Chlamydia trachomatis incl. IgG/RF absorbent	purified native MOMP antigen, serotype K	IgM	semi-quantitative	96 x 01
EI 2192-9601 A	Chlamydia pneumoniae	purified native antigens, strain "CWL-029"	IgA	semi-quantitative	96 x 01
EI 2192-9601 G	Chlamydia pneumoniae	purified native antigens, strain "CWL-029"	IgG	2/20/200 RU/ml	96 x 01
EI 2192-9601 M	Chlamydia pneumoniae incl. IgG/RF absorbent	purified native antigens, strain "CWL-029"	IgM	semi-quantitative	96 x 01
EI 2202-9601 A	Mycoplasma pneumoniae	detergent extract of strain "Mac ATCC 15531"	IgA	semi-quantitative	96 x 01
EI 2202-9601 G	Mycoplasma pneumoniae	detergent extract of strain "Mac ATCC 15531"	IgG	2/20/200 RU/ml	96 x 01
EI 2202-9601 M	Mycoplasma pneumoniae incl. IgG/RF absorbent	detergent extract of strain "Mac ATCC 15531"	IgM	semi-quantitative	96 x 01
EI 2212-9601 G	Trypanosoma cruzi	recombinant fusion protein of antigen epitopes from Trypanosoma cruzi	IgG	2/20/200 RU/ml	96 x 01

*) Currently not available as IVD in the European Union.

Microplate ELISA for Infectious Serology (Test Systems)					
Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Calibration	Format
EI 2320-9601-1 G	Echinococcus	purified native Echinococcus multilocularis antigen EmVF	IgG	semi-quantitative	96 x 01
EI 2410-9601 A	Toxoplasma gondii	purified antigens of Toxoplasma gondii	IgA	semi-quantitative	96 x 01
EI 2410-9601 G	Toxoplasma gondii	purified antigens of Toxoplasma gondii	IgG	1/10/200 IU/ml	96 x 01
EI 2410-9601 M	Toxoplasma gondii incl. IgG/RF absorbent	purified antigens of Toxoplasma gondii	IgM	semi-quantitative	96 x 01
EI 2410-9601 P	Toxoplasma gondii Screen	purified antigens of Toxoplasma gondii	IgAGM	semi-quantitative	96 x 01
EI 2410-9601-1 G	Toxoplasma gondii avidity determination	purified antigens of Toxoplasma gondii	IgG	1/10/200 IU/ml	96 x 01
EI 2410-9601-L G	Toxoplasma gondii antibody determination in CSF	purified antigens of Toxoplasma gondii	IgG	5/25/50/100 U	96 x 01
EI 2525-9601 A	Hepatitis E virus (HEV)	recombinant target antigens from Hepatitis E virus genotypes 1 and 3	IgA	semi-quantitative	96 x 01
EI 2525-9601 G	Hepatitis E virus (HEV)	recombinant target antigens from Hepatitis E virus genotypes 1 and 3	IgG	0,2/2/10/25 IU/ml	96 x 01
EI 2525-9601 M	Hepatitis E virus (HEV)	recombinant target antigens from Hepatitis E virus genotypes 1 and 3	IgM	semi-quantitative	96 x 01
EI 2525-9601 P	Hepatitis E virus (HEV)	recombinant target antigens from Hepatitis E virus genotypes 1 and 3	IgAGM	semi-quantitative	96 x 01
EI 2531-9601-1 A	Herpes simplex virus (HSV-1/2 Pool)	HSV-1: strain "Mac Intyre" (ATCC VR-539) HSV-2: strain "MS" (ATCC VR-540)	IgA	semi-quantitative	96 x 01
EI 2531-9601-1 G	Herpes simplex virus (HSV-1/2 Pool)	HSV-1: strain "Mac Intyre" (ATCC VR-539) HSV-2: strain "MS" (ATCC VR-540)	IgG	2/20/200 RU/ml	96 x 01
EI 2531-9601-1 L G	Herpes simplex virus (HSV-1/2 Pool) antibody determination in CSF	HSV-1: strain "Mac Intyre" (ATCC VR-539) HSV-2: strain "MS" (ATCC VR-540)	IgG	5-230 U/ml	96 x 01
EI 2531-9601-1 M	Herpes simplex virus (HSV-1/2 Pool) incl. IgG/RF absorbent	HSV-1: strain "Mac Intyre" (ATCC VR-539) HSV-2: strain "MS" (ATCC VR-540)	IgM	semi-quantitative	96 x 01
EI 2531-9601-2 G	Herpes simplex virus 1 (HSV-1)	glycoprotein C1	IgG	2/20/200 RU/ml	96 x 01
EI 2531-9601-2 M	Herpes simplex virus 1 (HSV-1) incl. IgG/RF absorbent	glycoprotein C1	IgM	semi-quantitative	96 x 01
EI 2531-9601-L G	Herpes simplex virus 1 (HSV-1) antibody determination in CSF	glycoprotein C1	IgG	5/25/50/100 U	96 x 01
EI 2532-9601-2 G	Herpes simplex virus 2 (HSV-2)	glycoprotein G2	IgG	2/20/200 RU/ml	96 x 01
EI 2532-9601-2 M	Herpes simplex virus 2 (HSV-2) incl. IgG/RF absorbent	glycoprotein G2	IgM	semi-quantitative	96 x 01
EI 2532-9601-L G	Herpes simplex virus 2 (HSV-2) antibody determination in CSF	glycoprotein G2	IgG	5/25/50/100 U	96 x 01
EI 2570-9601 G	Cytomegalovirus (CMV)	purified native antigens, strain "AD169"	IgG	2/20/200 RU/ml	96 x 01
EI 2570-9601 M	Cytomegalovirus (CMV) incl. IgG/RF absorbent	purified native antigens, strain "AD169"	IgM	semi-quantitative	96 x 01
EI 2570-9601-1 G	Cytomegalovirus (CMV) avidity determination	purified native antigens, strain "AD169"	IgG	2/20/200 RU/ml	96 x 01

Infectious serology

Microplate ELISA for Infectious Serology (Test Systems)						
Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Calibration	Format	
EI 2570-9601-L G	Cytomegalovirus (CMV) antibody determination in CSF	purified native antigens, strain "AD169"	IgG	5/25/50/100 U	96 x 01	
EI 2580-9601 G	Parvovirus B19	recombinant viral structural protein expressed in eukaryotic cells	IgG	1/5/25/100 IU/ml	96 x 01	
EI 2580-9601 M	Parvovirus B19 incl. IgG/RF absorbent	recombinant viral structural protein expressed in eukaryotic cells	IgM	semi-quantitative	96 x 01	
EI 2590-9601 G	Rubella virus	purified native antigens, strain "HPV-77"	IgG	1/10/50/200 IU/ml	96 x 01	
EI 2590-9601 M	Rubella virus incl. IgG/RF absorbent	purified native antigens, strain "HPV-77"	IgM	semi-quantitative	96 x 01	
EI 2590-9601-1 G	Rubella virus avidity determination	purified native antigens, strain "HPV-77"	IgG	1/10/50/200 IU/ml	96 x 01	
EI 2590-9601-2 M	Rubella virus glycoprotein incl. IgG/RF absorbent	native, purified glycoproteins, strain "HPV-77"	IgM	semi-quantitative	96 x 01	
EI 2590-9601-L G	Rubella virus antibody determination in CSF	purified native antigens, strain "HPV-77"	IgG	5-230 U	96 x 01	
EI 2604-9601 G	MERS coronavirus	purified S1 antigen of MERS coronavirus (MERS-CoV S1)	IgG	semi-quantitative	96 x 01	
EI 2610-9601 G	Measles virus	purified native antigens, strain "Edmonston" (ATCC VR-24)	IgG	50-5000 IU/I	96 x 01	
EI 2610-9601 M	Measles virus incl. IgG/RF absorbent	purified native antigens, strain "Edmonston" (ATCC VR-24)	IgM	semi-quantitative	96 x 01	
EI 2610-9601-1 G	Measles virus avidity determination	purified native antigens, strain "Edmonston" (ATCC VR-24)	IgG	50-5000 IU/I	96 x 01	
EI 2610-9601-4 M	Measles virus (NP) incl. IgG/RF absorbent	nucleoprotein from <i>S. cerevisiae</i>	IgM	semi-quantitative	96 x 01	
EI 2610-9601-L G	Measles virus antibody determination in CSF	purified native antigens, strain "Edmonston" (ATCC VR-24)	IgG	5-230 U	96 x 01	
EI 2630-9601 G	Mumps virus	purified native antigens, strain "Enders" (ATCC VR-106)	IgG	2/20/200 RU/ml	96 x 01	
EI 2630-9601 M	Mumps virus incl. IgG/RF absorbent	purified native antigens, strain "Enders" (ATCC VR-106)	IgM	semi-quantitative	96 x 01	
EI 2630-9601-3 G	Mumps virus AT	purified native antigens, strains "Enders" (ATCC VR-106) and "Jeryl Lynn"	IgG	2/20/200 RU/ml	96 x 01	
EI 2630-9601-5 M	Mumps virus G5 incl. IgG/RF absorbent	purified native antigens, genotype "G5"	IgM	semi-quantitative	96 x 01	
EI 2630-9601-L G	Mumps virus antibody determination in CSF	purified native antigens, strain "Enders" (ATCC VR-106)	IgG	5/25/50/100 U	96 x 01	
EI 2650-9601 A	Varicella zoster virus (VZV)	purified native antigens, strain "Ellen"	IgA	semi-quantitative	96 x 01	
EI 2650-9601 G	Varicella zoster virus (VZV)	purified native antigens, strain "Ellen"	IgG	10/100/500/5000 IU/I	96 x 01	
EI 2650-9601 M	Varicella zoster virus (VZV) incl. IgG/RF absorbent	purified native antigens, strain "VZ-10"	IgM	semi-quantitative	96 x 01	
EI 2650-9601-1 G	Varicella zoster virus (VZV) avidity determination	purified native antigens, strain "Ellen"	IgG	10/100/500/5000 IU/I	96 x 01	
EI 2650-9601-2 M	Varicella zoster virus (VZV) glycoprotein incl. IgG/RF absorbent	purified native glycoproteins, strain "Ellen"	IgM	semi-quantitative	96 x 01	
EI 2650-9601-L A	Varicella zoster virus (VZV) antibody determination in CSF	purified native antigens, strain "Ellen"	IgA	5-100 U	96 x 01	
EI 2650-9601-L G	Varicella zoster virus (VZV) antibody determination in CSF	purified native antigens, strain "Ellen"	IgG	5-230 U	96 x 01	

Microplate ELISA for Infectious Serology (Test Systems)					
Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Calibration	Format
EI 2650-9601-L M	Varicella zoster virus (VZV) antibody determination in CSF	cell lysate of a human fibroblast cell line, VZV wild strain	IgM	5/25/50/100 U	96 x 01
EI 2661-9601 G	TBE virus	highly purified TBE viral proteins (strain "K23")	IgG	2/20/200 RU/ml	96 x 01
EI 2661-9601 M	TBE virus incl. IgG/RF absorbent	highly purified TBE viral proteins (strain "K23")	IgM	semi-quantitative	96 x 01
EI 2661-9601-1 G	TBE virus avidity determination	highly purified TBE viral proteins (strain "K23")	IgG	2/20/200 RU/ml	96 x 01
EI 2661-9601-9 G	TBE virus Vienna	highly purified TBE viral proteins (strain "K23")	IgG	15-1000 VIEU/ml	96 x 01
EI 2661-9601-L G	TBE virus antibody determination in CSF	highly purified TBE viral proteins (strain "K23")	IgG	5/25/50/100 U	96 x 01
EI 2661-9601-L M	TBE virus antibody determination in CSF	highly purified TBE viral proteins (strain "K23")	IgM	5/25/50/100 U	96 x 01
EI 2662-9601 G	West Nile virus (WNV)	detergent-extracted glycoprotein E from the membrane fraction of human cells	IgG	2/20/200 RU/ml	96 x 01
EI 2662-9601 M	West Nile virus (WNV) incl. IgG/RF absorbent	detergent-extracted glycoprotein E from the membrane fraction of human cells	IgM	semi-quantitative	96 x 01
EI 2662-9601-1 G	West Nile virus (WNV) avidity determination	detergent-extracted glycoprotein E from the membrane fraction of human cells	IgG	2/20/200 RU/ml	96 x 01
EI 2663-9601 G *	Japanese encephalitis virus (JEV)	detergent-extracted glycoprotein E from the membrane fraction of human cells	IgG	2/20/200 RU/ml	96 x 01
EI 2663-9601 M *	Japanese encephalitis virus (JEV)	detergent-extracted glycoprotein E from the membrane fraction of human cells	IgM	semi-quantitative	96 x 01
EI 2667-9601 G	Usutu virus	purified glycoprotein E of Usutu virus	IgG	2/20/200 RU/ml	96 x 01
EI 266b-9601 A	Dengue virus (DENV)	highly purified preparation of Dengue virus particles (type 2)	IgA	semi-quantitative	96 x 01
EI 266b-9601 G	Dengue virus (DENV)	highly purified preparation of Dengue virus particles (type 2)	IgG	2/20/200 RU/ml	96 x 01
EI 266b-9601 M	Dengue virus (DENV) incl. IgG/RF absorbent	highly purified preparation of Dengue virus particles (type 2)	IgM	semi-quantitative	96 x 01
EI 2670-9601 A	Respiratory syncytial virus (RSV)	purified native antigens, strain "Long"	IgA	semi-quantitative	96 x 01
EI 2670-9601 G	Respiratory syncytial virus (RSV)	purified native antigens, strain "Long"	IgG	2/20/200 RU/ml	96 x 01
EI 2670-9601 M	Respiratory syncytial virus (RSV) incl. IgG/RF absorbent	purified native antigens, strain "Long"	IgM	semi-quantitative	96 x 01
EI 2680-9601 A	Adenovirus	purified native antigens, strain "Adenoid 6"	IgA	semi-quantitative	96 x 01
EI 2680-9601 G	Adenovirus	purified native antigens, strain "Adenoid 6"	IgG	2/20/200 RU/ml	96 x 01
EI 2680-9601 M	Adenovirus incl. IgG/RF absorbent	purified native antigens, strain "Adenoid 6"	IgM	semi-quantitative	96 x 01
EI 2691-9601 A	Influenza virus type A	strains "Texas" (H3N2), "California" (H1N1) and "Singapore" (H1N1)	IgA	semi-quantitative	96 x 01
EI 2691-9601 G	Influenza virus type A	strains "Texas" (H3N2), "California" (H1N1) and "Singapore" (H1N1)	IgG	2/20/200 RU/ml	96 x 01
EI 2691-9601 M	Influenza virus type A incl. IgG/RF absorbent	strains "Texas" (H3N2), "California" (H1N1) and "Singapore" (H1N1)	IgM	semi-quantitative	96 x 01
EI 2691-9601-1 A	Influenza virus types A and B (Pool)	see individual ELISA	IgA	semi-quantitative	96 x 01

*) Currently not available as IVD in the European Union.

Infectious serology

Microplate ELISA for Infectious Serology (Test Systems)

Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Calibration	Format
EI 2691-9601-1 G	Influenza virus types A and B (Pool)	see individual ELISA	IgG	2/20/200 RU/ml	96 x 01
EI 2691-9601-1 M	Influenza virus types A and B (Pool)	see individual ELISA	IgM	semi-quantitative	96 x 01
EI 2692-9601 A	Influenza virus type B	strain "Hong Kong 5/72"	IgA	semi-quantitative	96 x 01
EI 2692-9601 G	Influenza virus type B	strain "Hong Kong 5/72"	IgG	2/20/200 RU/ml	96 x 01
EI 2692-9601 M	Influenza virus type B incl. IgG/RF absorbent	strain "Hong Kong 5/72"	IgM	semi-quantitative	96 x 01
EI 2721-9601-1 A	Parainfluenza virus types 1 - 4 (Pool)	purified native antigens, strains "VP1", "Greer", "C-234" and "M25"	IgA	semi-quantitative	96 x 01
EI 2721-9601-1 G	Parainfluenza virus types 1 - 4 (Pool)	purified native antigens, strains "VP1", "Greer", "C-234" and "M25"	IgG	2/20/200 RU/ml	96 x 01
EI 2721-9601-1 M	Parainfluenza virus types 1 - 4 (Pool) incl. IgG/RF absorbent	purified native antigens, strains "VP1", "Greer", "C-234" and "M25"	IgM	semi-quantitative	96 x 01
EI 2730-9601-1 A	Enterovirus	purified VP1 of ECHO 6 / Coxsackie B5 virus	IgA	semi-quantitative	96 x 01
EI 2730-9601-1 G	Enterovirus	purified VP1 of ECHO 6 / Coxsackie B5 virus	IgG	semi-quantitative	96 x 01
EI 2730-9601-1 M	Enterovirus incl. IgG/RF absorbent	purified VP1 of ECHO 6 / Coxsackie B5 virus	IgM	semi-quantitative	96 x 01
EI 278h-9601-1 G	Hantavirus Pool 1 "Eurasia"	purified recombinant nucleocapsid proteins from strains Hantaan HTNV Fojnica, Dobrava DOBV Slovenia, Puumala PUUV Vranica	IgG	2/20/200 RU/ml	96 x 01
EI 278h-9601-1 M	Hantavirus Pool 1 "Eurasia" incl. IgG/RF absorbent	purified recombinant nucleocapsid proteins from strains Hantaan HTNV Fojnica, Dobrava DOBV Slovenia, Puumala PUUV Vranica	IgM	semi-quantitative	96 x 01
EI 278h-9601-2 G	Hantavirus Pool 2 "America"	purified recombinant nucleocapsid proteins from strains Andes ANDV and Sin Nombre SNV	IgG	2/20/200 RU/ml	96 x 01
EI 278h-9601-2 M	Hantavirus Pool 2 "America" incl. IgG/RF absorbent	purified recombinant nucleocapsid proteins from strains Andes ANDV and Sin Nombre SNV	IgM	semi-quantitative	96 x 01
EI 2791-9601 A	Epstein-Barr virus capsid antigen (EBV-CA)	native, mixture of several viral capsid antigens	IgA	semi-quantitative	96 x 01
EI 2791-9601 G	Epstein-Barr virus capsid antigen (EBV-CA)	native, mixture of several viral capsid antigens	IgG	2/20/200 RU/ml	96 x 01
EI 2791-9601 M	Epstein-Barr virus capsid antigen (EBV-CA) incl. IgG/RF absorbent	native, gp125 of EBV infected P3HR1 cells	IgM	semi-quantitative	96 x 01
EI 2791-9601-1 G	Epstein-Barr virus capsid antigen (EBV-CA) avidity determination	native, mixture of several viral capsid antigens	IgG	2/20/200 RU/ml	96 x 01
EI 2791-9601-L G	Epstein-Barr virus capsid antigen (EBV-CA) antibody determination in CSF	native, mixture of several viral capsid antigens	IgG	5/25/50/100 U	96 x 01
EI 2793-9601 G	Epstein-Barr virus nuclear antigen (EBNA-1)	recombinant EBNA-1 from EBV	IgG	2/20/200 RU/ml	96 x 01
EI 2795-9601 A	Epstein-Barr virus early antigen (EBV-EA)	recombinant, EBV-EA-D (diffuse), expression in E. coli	IgA	semi-quantitative	96 x 01
EI 2795-9601 G	Epstein-Barr virus early antigen (EBV-EA)	recombinant, EBV-EA-D (diffuse), expression in E. coli	IgG	2/20/200 RU/ml	96 x 01

Microplate ELISA for Infectious Serology (Test Systems)

Order No.	Antibodies against	Antigen and Antigen Source	Ig Class	Calibration	Format
EI 2795-9601 M	Epstein-Barr virus early antigen (EBV-EA) incl. IgG/RF absorbent	recombinant, EBV-EA-D (diffuse), expression in E. coli	IgM	semi-quantitative	96 x 01
EI 293a-9601 G	Chikungunya virus (CHIKV)	recombinant structural protein from Chikungunya virus	IgG	2/20/200 RU/ml	96 x 01
EI 293a-9601 M	Chikungunya virus (CHIKV) incl. IgG/RF absorbent	recombinant structural protein from Chikungunya virus	IgM	semi-quantitative	96 x 01

Microplate ELISA for the Determination of Infectious Diseases, Antigen Detection (Test Systems)

Order No.	Analyte	Calibration	Format
EQ 266a-9601-1	Dengue virus NS1 (DENV)	1/10/100 RU/ml	96 x 01
EQ 6811-9601-L	CXCL13 determination in CSF	0/10/30/90/200/500 pg/ml	96 x 01

ELISA Controls for Infectious Serology

Order No.	Control (Ready for use)	Ig Class	Format
CK2111-0220-L G	CSQ pair of controls anti-Treponema pallidum (IgG)	IgG	2 x 2 ml, ready for use
CK2132-0220-L G	CSQ pair of controls anti-Borrelia (IgG)	IgG	2 x 2 ml, ready for use
CK2132-0220-L M	CSQ pair of controls anti-Borrelia (IgM)	IgM	2 x 2 ml, ready for use
CK2410-0220-L G	CSQ pair of controls anti-Toxoplasma gondii (IgG)	IgG	2 x 2 ml, ready for use
CK2531-0220-1 L G	CSQ pair of controls anti-HSV-1/2 Pool (IgG)	IgG	2 x 2 ml, ready for use
CK2531-0220-L G	CSQ pair of controls anti-HSV-1 (IgG)	IgG	2 x 2 ml, ready for use
CK2532-0220-L G	CSQ pair of controls anti-HSV-2 (IgG)	IgG	2 x 2 ml, ready for use
CK2570-0220-L G	CSQ pair of controls anti-Cytomegalovirus (IgG)	IgG	2 x 2 ml, ready for use
CK2590-0220-L G	CSQ pair of controls anti-Rubella virus (IgG)	IgG	2 x 2 ml, ready for use
CK2610-0220-L G	CSQ pair of controls anti-Measles virus (IgG)	IgG	2 x 2 ml, ready for use
CK2630-0220-L G	CSQ pair of controls anti-Mumps virus (IgG)	IgG	2 x 2 ml, ready for use
CK2650-0220-L G	CSQ pair of controls anti-VZV (IgG)	IgG	2 x 2 ml, ready for use
CK2661-0220-9 L G	CSQ pair of controls anti-TBE virus Vienna (IgG)	IgG	2 x 2 ml, ready for use
CK2661-0220-L G	CSQ pair of controls anti-TBE virus (IgG)	IgG	2 x 2 ml, ready for use
CK2661-0220-L M	CSQ pair of controls anti-TBE virus (IgM)	IgM	2 x 2 ml, ready for use
CK2791-0220-L G	CSQ pair of controls anti-EBV-CA (IgG)	IgG	2 x 2 ml, ready for use

Diagnostics for Indirect Immunofluorescence: Infectious Serology					
Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2050-1005 G FI 2050-1010 G FK2050-1005 FK2050-1010	Bordetella pertussis	IgG	bacterial smear	Bordetella pertussis	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2050-1005-1 G FI 2050-1010-1 G FK2050-1005-1 FK2050-1010-1	Bordetella pertussis Bordetella parapertussis	IgG	bacterial smears (2 BIOCHIPs per field)	B. pertussis B. parapertussis	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2055-1005 G FI 2055-1010 G FI 2055-2005 G FK2055-1005 FK2055-1010 FK2055-2005	Bordetella parapertussis	IgG	bacterial smear	Bordetella parapertussis	10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides)
FI 2080-1005 A FI 2080-1005 G FI 2080-1005 M	Helicobacter pylori	IgA IgG IgM	bacterial smear	Helicobacter pylori	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2090-1005-1 G	Campylobacter jejuni Campylobacter coli	IgG	bacterial smears (2 BIOCHIPs per field)	C. jejuni C. coli	10 x 05 (test system)
FI 2091-1005 A FI 2091-1005 G	Campylobacter jejuni	IgA IgG	bacterial smear	Campylobacter jejuni	10 x 05 (test system) 10 x 05 (test system)
FI 2111-1003 G FI 2111-1005 G FI 2111-1010 G FI 2111-1003 M FI 2111-1005 M FI 2111-1010 M FK2111-1003 FK2111-1005 FK2111-1010	Treponema pallidum (FTA-ABS)	IgG IgM	bacterial smear verification BIOCHIP (2 BIOCHIPs per field)	T. pallidum	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2112-1005 G FI 2112-1010 G FI 2112-1005 M FI 2112-1010 M	Treponema pallidum (FTA-ABS)	IgG IgM	bacterial smears verification BIOCHIP (3 BIOCHIPs per field)	T. pallidum T. phagedenis T. pallidum T. phagedenis	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 2131-1005-1 G	EUROPLUS Borrelia afzelii VlsE antigen	IgG	2 BIOCHIPs per field: bacterial smear VlsE BIOCHIPs	B. afzelii recombinant	10 x 05 (test system)
FI 2131-1005-2 M	EUROPLUS Borrelia afzelii OspC antigen	IgM	2 BIOCHIPs per field: bacterial smear OspC BIOCHIPs	B. afzelii B. burgdorferi	10 x 05 (test system)
FI 2132-1005 G FI 2132-1010 G FI 2132-1005 M FI 2132-1010 M FK2132-1005 FK2132-1010	Borrelia burgdorferi (CH)	IgG IgM	bacterial smear verification BIOCHIP (2 BIOCHIPs per field)	Borrelia burgdorferi (CH)	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2136-1005-1 G FI 2136-1010-1 G FI 2136-1005-1 M FI 2136-1010-1 M	EUROPLUS Borrelia afzelii Borrelia burgdorferi (USA) OspC antigen VlsE antigen	IgG IgM	4 BIOCHIPs per field: bacterial smear bacterial smear OspC BIOCHIPs VlsE BIOCHIPs	B. afzelii B. burgd. (USA) B. burgdorferi recombinant	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 2138-1005-2 G FI 2138-1005-2 M	Borrelia afzelii Borrelia burgdorferi (CH) Borrelia burgdorferi (USA) Borrelia garinii	IgG IgM	bacterial smears (4 BIOCHIPs per field)	B. afzelii B. burgdorferi (CH) B. burgdorferi (USA) B. garinii	10 x 05 (test system) 10 x 05 (test system)
FI 2141-1003-1 G FI 2141-1005-1 G FI 2141-1010-1 G FK2141-1003-1 FK2141-1005-1 FK2141-1010-1	Listeria monocytogenes 1/2a and 4b	IgG	bacterial smears (2 BIOCHIPs per field)	Listeria monocytogenes 1/2a and 4b	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides)

Infectious serology

Diagnostics for Indirect Immunofluorescence: Infectious Serology

Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2150-1001 P FI 2150-2001 P FK 2150-1001 FK 2150-2001	"BIOCHIP Sequence Legionella pneumophila" serotypes 1 - 14	IgAGM	bacterial smears (1 BIOCHIP per serotype) verification BIOCHIP	Legionella pneumophila	10 x 01 (test system) 20 x 01 (test system) 10 x 01 (single slides) 20 x 01 (single slides)
FI 2150-1003-3 P FI 2150-1005-3 P FI 2150-2005-3 P FK 2150-1003-3 FK 2150-1005-3 FK 2150-2005-3	Legionella pneumophila mixture 1-4-6-8 mixture 2-3-5-7 mixture 9-11-13 mixture 10-12-14	IgAGM	bacterial smears verification BIOCHIP (5 BIOCHIPS per field)	Legionella pneumophila	10 x 03 (test system) 10 x 05 (test system) 20 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 20 x 05 (single slides)
FI 2150-1005-4 G FI 2150-1005-4 P	"Legionella Mosaic 4" mixture 1-2-3-4-5-6-7 mixture 8-9-10-11-12-13-14 mixture L. non-pneumophila	IgG IgAGM	4 BIOCHIPS per field: bacterial smear bacterial smear bacterial smear verification BIOCHIP	L. pneumophila L. pneumophila 6 L. non-pneum. sp.	10 x 05 (test system) 10 x 05 (test system)
FI 215b-1010 P	Legionella pneumophila mixture 1-4-6-8	IgAGM	bacterial smear verification BIOCHIP (2 BIOCHIPS per field)	Legionella pneumophila	10 x 10 (test system)
FI 215b-1003-1 P FI 215b-1005-1 P FI 215b-1010-1 P FI 215b-2005-1 P	Legionella pneumophila mixture 1-4-6-8 mixture 2-3-5-7	IgAGM	bacterial smears verification BIOCHIP (3 BIOCHIPS per field)	Legionella pneumophila	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system)
FI 216f-1005-1 P	"Mosaic Legionella non-pneumophila" Legionella jordanis Legionella bozemani Legionella gormanii Legionella micdadei Legionella dumoffii Legionella longbeachae	IgAGM	6 BIOCHIPS per field: bacterial smears	L. jordanis L. bozemani L. gormanii L. micdadei L. dumoffii L. longbeachae	10 x 05 (test system)
FI 2173-1005-1 G *	"BIOCHIP Mosaic" Yersinia enterocolitica O:3, O:4, O:6, O:9 (for diagnosing various forms of arthritis)	IgG	4 BIOCHIPS per field: bacterial smears	Yersinia enterocolitica	10 x 05 (test system)
FI 2191-1003 A FI 2191-1005 A FI 2191-1010 A FI 2191-1003 G FI 2191-1005 G FI 2191-1010 G FI 2191-1003 M FI 2191-1005 M FI 2191-1010 M FK 2191-1003 FK 2191-1005 FK 2191-1010	Chlamydia trachomatis	IgA	infected cells	EU 40	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2191-1003-2 A FI 2191-1005-2 A FI 2191-1010-2 A FI 2191-2005-2 A FI 2191-1003-2 G FI 2191-1005-2 G FI 2191-1010-2 G FI 2191-2005-2 G FI 2191-1003-2 M FI 2191-1005-2 M FI 2191-1010-2 M FI 2191-2005-2 M FK 2191-1003-2 FK 2191-1005-2 FK 2191-1010-2 FK 2191-2005-2	Chlamydia trachomatis Chlamydia pneumoniae	IgA IgG IgM	infected cells infected cells (2 BIOCHIPS per field)	EU 40 EU 38	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides)

*) Currently not available as IVD in the European Union.

Diagnostics for Indirect Immunofluorescence: Infectious Serology

Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2191-1005-3 A FI 2191-1010-3 A FI 2191-1005-3 G FI 2191-1010-3 G FI 2191-1005-3 M FI 2191-1010-3 M FK 2191-1005-3 FK 2191-1010-3	"Anti-Chlamydia MIF" <i>Chlamydia trachomatis</i> <i>Chlamydia pneumoniae</i> <i>Chlamydia psittaci</i>	IgA IgG IgM	elementary bodies and non-infected cells (4 BIOCHIPs per field)	EU 40 EU 40 EU 40	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2191-1005-80 A FI 2191-1005-80 G FI 2191-1005-80 M	<i>Chlamydia trachomatis</i>	IgA IgG IgM	elementary bodies (MIF) non-infected cells (2 BIOCHIPs per field)	EU 40 EU 40	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2192-1003 A FI 2192-1005 A FI 2192-1010 A FI 2192-1003 G FI 2192-1005 G FI 2192-1010 G FI 2192-1003 M FI 2192-1005 M FI 2192-1010 M FK 2192-1003 FK 2192-1005 FK 2192-1010	<i>Chlamydia pneumoniae</i>	IgA IgG IgM	infected cells	EU 38	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2192-1005-80 A FI 2192-1005-80 G FI 2192-1005-80 M	<i>Chlamydia pneumoniae</i>	IgA IgG IgM	elementary bodies (MIF) non-infected cells (2 BIOCHIPs per field)	EU 40 EU 40	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2193-1005-80 A FI 2193-1005-80 G FI 2193-1005-80 M	<i>Chlamydia psittaci</i>	IgA IgG IgM	elementary bodies (MIF) non-infected cells (2 BIOCHIPs per field)	EU 40 EU 40	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 219b-1005 G FI 219b-1010 G FK 219b-1005 G FK 219b-1010 G FI 219b-1005 M FI 219b-1010 M FK 219b-1005 M FK 219b-1010 M	<i>Bartonella henselae</i>	IgG IgM	infected cells infected and non-infected cells (2 BIOCHIPs per field)	EU 70	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 219b-1005-1 G FI 219b-1010-1 G FK 219b-1005-1 G FK 219b-1010-1 G FI 219b-1005-1 M FI 219b-1010-1 M FK 219b-1005-1 M FK 219b-1010-1 M	<i>Bartonella henselae</i> <i>Bartonella quintana</i>	IgG IgM	infected cells infected cells (2 BIOCHIPs per field) infected and non-infected cells (4 BIOCHIPs per field)	EU 70 EU 70 EU 70 EU 38	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 219d-1005 G FI 219d-1005 M	<i>Bartonella quintana</i>	IgG IgM	infected cells infected and non-infected cells (2 BIOCHIPs per field)	EU 70 EU 38	10 x 05 (test system) 10 x 05 (test system)
FI 2201-1005 A FI 2201-1005 G FI 2201-1005 M	<i>Mycoplasma hominis</i>	IgA IgG IgM	infected and non-infected cells (2 BIOCHIPs per field)	EU 38	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2201-1005-1 A FI 2201-1010-1 A FI 2201-1005-1 G FI 2201-1010-1 G FI 2201-1005-1 M FI 2201-1010-1 M	<i>Mycoplasma hominis</i> <i>Ureaplasma urealyticum</i>	IgA IgG IgM	infected cells infected cells non-infected cells (3 BIOCHIPs per field)	EU 38 EU 38 EU 38	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)

Infectious serology

Diagnostics for Indirect Immunofluorescence: Infectious Serology

Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2202-1003 A FI 2202-1005 A FI 2202-1010 A FI 2202-2005 A FI 2202-1003 G FI 2202-1005 G FI 2202-1010 G FI 2202-2005 G FI 2202-1003 M FI 2202-1005 M FI 2202-1010 M FI 2202-2005 M FK2202-1003 FK2202-1005 FK2202-1010 FK2202-2005	Mycoplasma pneumoniae	IgA	bacteria	Mycoplasma pneumoniae	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides)
FI 2205-1005 A FI 2205-1005 G FI 2205-1005 M	Ureaplasma urealyticum	IgA IgG IgM	infected and non-infected cells (2 BIOCHIPS per field)	EU 38	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2231-1005 A FI 2231-1010 A FI 2231-1005 G FI 2231-1010 G FI 2231-1005 M FI 2231-1010 M FK2231-1005 FK2231-1010	Leishmania donovani (promastigote)	IgA IgG IgM	protozoan smear	Leishmania donovani	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2300-1005 G FI 2300-1005 M FK2300-1005	Schistosoma mansoni	IgG IgM	frozen sections	Schistosoma mansoni, adult	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (single slides)
FI 2320-1005 A FI 2320-1003 G FI 2320-1005 G FI 2320-1005 M	Echinococcus granulosus	IgA IgG IgM	frozen sections	Echinococcus protoscolices	10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2410-1005 A * FI 2410-1010 A * FI 2410-1005 G FI 2410-1010 G FI 2410-1005 M FI 2410-1010 M FI 2410-1005 X FI 2410-1010 X FK2410-1005 FK2410-1010	Toxoplasma gondii	IgA IgG IgM	protozoan smear avidity test	Toxoplasma gondii	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2410-1005-3 G	"TO.R.C.H. Profile" Toxoplasma gondii Rubella virus Cytomegalovirus HSV mixture (1+2)	IgG	4 BIOCHIPS per field: protozoan smear infected cells infected cells infected cells	T. gondii EU 13 EU 168 EU 38	10 x 05 (test system)
FI 2531-1005 G FI 2531-1005 M	Herpes simplex virus 1 (HSV-1)	IgG IgM	infected cells	EU 38	10 x 05 (test system) 10 x 05 (test system)
FI 2531-1003-1 G FI 2531-1005-1 G FI 2531-1010-1 G FI 2531-2005-1 G FI 2531-1003-1 M FI 2531-1005-1 M FI 2531-1010-1 M FI 2531-2005-1 M FK2531-1003-1 FK2531-1005-1 FK2531-1010-1 FK2531-2005-1	"BIOCHIP Mosaic" HSV-1/HSV-2	IgG IgM	2 BIOCHIPS per field: infected cells	EU 38 EU 38	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides)
FI 2532-1005 G FI 2532-1005 M	Herpes simplex virus 2 (HSV-2)	IgG IgM	infected cells	EU 38	10 x 05 (test system) 10 x 05 (test system)

*) Currently not available as IVD in the European Union.

Diagnostics for Indirect Immunofluorescence: Infectious Serology

Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2536-1003 G FI 2536-1005 G FI 2536-1010 G FI 2536-2005 G FI 2536-2010 G FI 2536-1003 M FI 2536-1005 M FI 2536-1010 M FI 2536-2005 M FI 2536-2010 M FK 2536-1003 FK 2536-1005 FK 2536-1010 FK 2536-2005 FK 2536-2010	Human herpes virus 6 (HHV-6)	IgG	infected cells	EU 30	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 20 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 20 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides) 20 x 10 (single slides)
FI 2570-1003 A FI 2570-1005 A FI 2570-1010 A FI 2570-1003 G FI 2570-1005 G FI 2570-1010 G FI 2570-1003 M FI 2570-1005 M FI 2570-1010 M FI 2570-1005 X	Cytomegalovirus (CMV)	IgA	infected cells	EU 168	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system)
FI 2590-1005 G FI 2590-1005 X	Rubella virus	IgG avidity test	infected cells	EU 13	10 x 05 (test system) 10 x 05 (test system)
FI 2601-1010 G FI 2601-1010 M	SARS coronavirus	IgG IgM	infected and non-infected cells (2 BIOCHIPS per field)	EU 14	10 x 10 (test system) 10 x 10 (test system)
FI 2604-1005 G FI 2604-1010 G FI 2604-1005 M FI 2604-1010 M	MERS coronavirus	IgG IgM	infected and non-infected cells (2 BIOCHIPS per field)	EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 2610-1005 G FI 2610-1005 M	Measles virus	IgG IgM	infected cells	EU 38	10 x 05 (test system) 10 x 05 (test system)
FI 2630-1003 G FI 2630-1005 G FI 2630-1010 G FI 2630-1003 M FI 2630-1005 M FI 2630-1010 M FK 2630-1003 FK 2630-1005 FK 2630-1010	Mumps virus	IgG IgM	infected cells	EU 13 EU 38	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2650-1003 A FI 2650-1005 A FI 2650-1010 A FI 2650-1003 G FI 2650-1005 G FI 2650-1010 G FI 2650-1003 M FI 2650-1005 M FI 2650-1010 M FI 2650-1005 X FK 2650-1003 FK 2650-1005 FK 2650-1010	Varicella zoster virus (VZV)	IgA IgG IgM avidity test	infected cells	EU 168	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2661-1005 G FI 2661-1010 G FI 2661-1005 M FI 2661-1010 M FK 2661-1005 FK 2661-1010	TBE virus	IgG IgM	infected and non-infected cells (2 BIOCHIPS per field)	EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2661-1005-1 G FI 2661-1010-1 G FI 2661-1005-1 M FI 2661-1010-1 M	"Flavivirus Mosaic 1" TBE virus West Nile virus (WNV) Japanese encephalitis virus (JEV) Yellow fever virus (YFV)	IgG IgM	4 BIOCHIPS per field: infected cells infected cells infected cells infected cells	EU 14 EU 14 EU 14 EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)

Infectious serology

Diagnostics for Indirect Immunofluorescence: Infectious Serology					
Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2661-1005-2 G FI 2661-2005-2 G FI 2661-1005-2 M FI 2661-2005-2 M	"Flavivirus Profile 2" upper row: TBE virus West Nile virus (WNV) Japanese encephalitis virus (JEV) Yellow fever virus (YFV) bottom row: Dengue virus types 1 - 4 (DENV)	IgG IgM	infected cells infected cells infected cells infected cells infected cells	EU 14 EU 14 EU 14 EU 14 EU 14	10 x 05 (test system) 20 x 05 (test system) 10 x 05 (test system) 20 x 05 (test system)
FI 2661-1005-3 G FI 2661-1010-3 G FI 2661-1005-3 M FI 2661-1010-3 M FK 2661-1005-3 FK 2661-1010-3	"Flavivirus Mosaic 3" TBE virus West Nile virus (WNV) Japanese encephalitis virus (JEV) Yellow fever virus (YFV) Dengue virus types 1 - 4 (DENV)	IgG IgM	9 BIOCHIPS per field: infected cells infected cells infected cells infected cells infected cells non-infected cells	EU 14 EU 14 EU 14 EU 14 EU 14 EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2662-1005 G FI 2662-1010 G FI 2662-1005 M FI 2662-1010 M FI 2662-1005 X FI 2662-1010 X	West Nile virus (WNV)	IgG IgM	infected and non-infected cells (2 BIOCHIPS per field)	EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
avidity test					
FI 2663-1005 G FI 2663-1005 M	Japanese encephalitis virus (JEV)	IgG IgM	infected and non-infected cells (2 BIOCHIPS per field)	EU 14	10 x 05 (test system) 10 x 05 (test system)
FI 2664-1010-1 G * FI 2664-1010-1 M *	"Arboviren-Mosaic Amerika 1" St. Louis encephalitis virus La crosse virus	IgG IgM	3 BIOCHIPS per field: infected cells infected cells non-infected cells	EU 14 EU 14 EU 14	10 x 10 (test system) 10 x 10 (test system)
FI 2665-1005 G FI 2665-1010 G FI 2665-1005 M FI 2665-1010 M	Yellow fever virus (YFV)	IgG IgM	infected and non-infected cells (2 BIOCHIPS per field)	EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 2666-1005-1 G * FI 2666-1005-1 M *	"Arbovirus Mosaic Australia" Murray Valley encephalitis virus (MVEV) Ross River virus (RRV)	IgG IgM	3 BIOCHIPS per field: infected cells infected cells non-infected cells	EU 14 EU 14 EU 14	10 x 05 (test system) 10 x 05 (test system)
FI 266a-1005-1 G FI 266a-1010-1 G FI 266a-2005-1 G FI 266a-1005-1 M FI 266a-1010-1 M FI 266a-2005-1 M	"Mosaic Dengue virus" types 1 - 4 (DENV)	IgG IgM	4 BIOCHIPS per field: infected cells	EU 14	10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system)
FI 2670-1003 A FI 2670-1005 A FI 2670-1003 G FI 2670-1005 G FI 2670-1003 M FI 2670-1005 M FK 2670-1003 FK 2670-1005	Respiratory syncytial virus (RSV)	IgA IgG IgM	infected cells	EU 38	10 x 03 (test system) 10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides)
FI 2680-1003 A FI 2680-1005 A FI 2680-1003 G FI 2680-1005 G FI 2680-1003 M FI 2680-1005 M	Adenovirus type 3	IgA IgG IgM	infected cells	EU 38	10 x 03 (test system) 10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system)
FI 2691-1005 A FI 2691-1005 G FI 2691-1005 M FK 2691-1005	Influenza virus type A	IgA IgG IgM	infected cells	EU 50	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system) 10 x 05 (single slides)

*) Currently not available as IVD in the European Union.

Diagnostics for Indirect Immunofluorescence: Infectious Serology

Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2691-1005-1 A FI 2691-1010-1 A FI 2691-1005-1 G FI 2691-1010-1 G FI 2691-1005-1 M FI 2691-1010-1 M	Influenza virus type A Influenza virus type B	IgA IgG IgM	infected cells infected cells (2 BIOCHIPS per field)	EU 50 EU 50	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 2692-1005 A FI 2692-1005 G FI 2692-1005 M	Influenza virus type B	IgA IgG IgM	infected cells	EU 13	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2721-1005-1 A FI 2721-1005-1 G FI 2721-1005-1 M	"Mosaic Parainfluenza virus" types 1 - 4	IgA IgG IgM	(4 BIOCHIPS per field) infected cells	EU 18/9	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2730-1003-1 A FI 2730-1005-1 A FI 2730-1003-1 G FI 2730-1005-1 G FI 2730-1003-1 M FI 2730-1005-1 M FK2730-1003-1 FK2730-1005-1	"Mosaic Coxsackie virus" types A7, A9, A16, A24, B1, B2, B3, B4, B5	IgA IgG IgM	9 BIOCHIPS per field: infected cells	EU 38	10 x 03 (test system) 10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides)
FI 2730-1005-2 A FI 2730-1003-2 G FI 2730-1005-2 G FI 2730-2005-2 G FI 2730-1003-2 M FI 2730-1005-2 M FI 2730-2005-2 M	"Mosaic Coxsackie virus A types" types A7, A9, A16, A24	IgA IgG IgM	4 BIOCHIPS per field: infected cells	EU 38	10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 20 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 20 x 05 (test system)
FI 2730-1005-3 A FI 2730-1003-3 G FI 2730-1005-3 G FI 2730-2005-3 G FI 2730-1003-3 M FI 2730-1005-3 M FI 2730-2005-3 M	"Mosaic Coxsackie virus B types" types B1, B2, B3, B4, B5, B6	IgA IgG IgM	6 BIOCHIPS per field: infected cells	EU 38	10 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 20 x 05 (test system) 10 x 03 (test system) 10 x 05 (test system) 20 x 05 (test system)
FI 2730-1005-4 A FI 2730-1005-4 G FI 2730-1005-4 M	Coxsackie virus type A7 Coxsackie virus type B1	IgA IgG IgM	infected cells infected cells (2 BIOCHIPS per field)	EU 38 EU 38	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2730-1005-5 A FI 2730-1010-5 A FI 2730-1005-5 G FI 2730-1010-5 G FI 2730-1005-5 M FI 2730-1010-5 M FK2730-1005-5 FK2730-1010-5	"Enterovirus Mosaic 1" Coxsackie virus type A7 Coxsackie virus type B1 Echo virus type 7	IgA IgG IgM	3 BIOCHIPS per field: infected cells infected cells infected cells	EU 38 EU 38 EU 38	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2731-1005 A FI 2731-1005 G FI 2731-1005 M	Coxsackie virus type B1	IgA IgG IgM	infected cells	EU 38	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 2737-1005 A FI 2737-1005 G FI 2737-1005 M	Coxsackie virus type A7	IgA IgG IgM	infected cells	EU 38	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 275a-1005 A FI 275a-1005 G FI 275a-1005 M	Echo virus type 7	IgA IgG IgM	infected cells	EU 38	10 x 05 (test system) 10 x 05 (test system) 10 x 05 (test system)
FI 277a-1005-1 G FI 277a-1010-1 G FI 277a-1005-1 M FI 277a-1010-1 M	"Sandfly fever virus Mosaic 1" types Sicilian, Naples, Toscana, Cyprus	IgG IgM	4 BIOCHIPS per field: infected cells	EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 278h-1003-1 G FI 278h-1005-1 G FI 278h-1010-1 G FI 278h-1003-1 M FI 278h-1005-1 M FI 278h-1010-1 M FK278h-1003-1 FK278h-1005-1 FK278h-1010-1	"Hantavirus Mosaic 1" types Hantaan, Sin Nombre, Puumala, Dobrava, Seoul, Saaremaa	IgG IgM	6 BIOCHIPS per field: infected cells	EU 14	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides)

Infectious serology

Diagnostics for Indirect Immunofluorescence: Infectious Serology

Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 278h-1005-2 G FI 278h-1010-2 G FI 278h-1005-2 M FI 278h-1010-2 M FK 278h-1005-2 FK 278h-1010-2	"Hantavirus Mosaic 2: Eurasia" types Hantaan, Puumala, Dobrava, Seoul, Saaremaa	IgG IgM	6 BIOCHIPS per field: infected and non-infected cells	EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 278m-1005-3 G FI 278m-1005-3 M	"Hantavirus Mosaic 3: America" types Sin Nombre, Andes	IgG IgM	2 BIOCHIPS per field: infected cells	EU 14	10 x 05 (test system) 10 x 05 (test system)
FI 2791-1003 A FI 2791-1005 A FI 2791-1010 A FK 2791-1003 A FK 2791-1005 A FK 2791-1010 A FI 2791-1003 G FI 2791-1005 G FI 2791-1010 G FI 2791-2010 G FK 2791-1003 G FK 2791-1005 G FK 2791-1010 G FK 2791-2010 G FI 2791-1003 M FI 2791-1005 M FI 2791-1010 M FI 2791-2005 M FK 2791-1003 M FK 2791-1005 M FK 2791-1010 M FK 2791-2005 M FI 2791-1005 X	Epstein-Barr virus capsid antigen (EBV-CA)	IgA	expressing cells	P3HR1	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 10 (single slides) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides) 10 x 05 (test system)
FI 2791-1003-2 A FI 2791-1005-2 A FI 2791-1010-2 A FI 2791-2005-2 A FI 2791-2010-2 A FK 2791-1003-2 A FK 2791-1005-2 A FK 2791-1010-2 A FK 2791-2005-2 A FK 2791-2010-2 A FI 2791-1003-2 G FI 2791-1005-2 G FI 2791-1010-2 G FI 2791-2005-2 G FK 2791-1003-2 G FK 2791-1005-2 G FK 2791-1010-2 G FK 2791-2005-2 G FI 2791-1005-2 X	EBV capsid antigen (EBV-CA) EBV early antigen (EBV-EA)	IgA	expressing cells (2 BIOCHIPS per field)	P3HR1 EU 33	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 20 x 10 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides) 20 x 10 (single slides) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 03 (single slides) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides) 10 x 05 (test system)
FI 2791-1005-20 G FI 2791-1010-20 G FK 2791-1005-20 G FK 2791-1010-20 G FI 2791-1005-20 M FI 2791-1010-20 M FK 2791-1005-20 M FK 2791-1010-20 M	"EUROPLUS" EBV capsid antigen (EBV-CA) gp125 antigen p19 antigen	IgG IgM	4 BIOCHIPS per field: expressing cells gp125 BIOCHIPS p19 BIOCHIPS	P3HR1 native recombinant EU 120	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2793-1010 C FK 2793-1010	Epstein-Barr virus nuclear antigen (EBNA, complement-fixing antibodies)	IgG	expressing cells	Raji	10 x 10 (test system) 10 x 10 (single slides)
FI 2795-1005 A FI 2795-1010 A FI 2795-1005 G FI 2795-1010 G FI 2795-1005 X FK 2795-1005 FK 2795-1010	Epstein-Barr virus early antigen (EBV-EA)	IgA IgG	expressing cells	EU 33	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 05 (single slides) 10 x 10 (single slides)
FI 2795-1005 X FK 2795-1005 FK 2795-1010			avidity test		

Diagnostics for Indirect Immunofluorescence: Infectious Serology

Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2799-1001-1 X FI 2799-1002-1 X FI 2799-2001-1 X FI 2799-2002-1 X	"BIOCHIP Sequence EBV" fields A and B: EBV-CA (IgG) field C: EBV-CA (IgM) field D: EBV-EA field E: EBNA	avidity test	expressing cells expressing cells expressing cells expressing cells	P3HR1 P3HR1 EU 33 Raji	10 x 01 (test system) 10 x 02 (test system) 20 x 01 (test system) 20 x 02 (test system)
	format 1001: per slide one patient format 1002: per slide two patients				
FI 2799-1001-21 X FI 2799-1002-21 X FI 2799-2001-21 X FI 2799-2002-21 X	"EUROPLUS BIOCHIP Sequence EBV" field A: EBV-CA (IgG), gp125 ag, p19 ag field B: EBV-CA (IgG) field C: EBV-CA (IgM), gp125 ag, p19 ag field D: EBV-EA field E: EBNA	avidity test	expr. cells, gp125/p19/ ag-free BIOCHIP expressing cells expressing cells expr. cells, gp125/p19/ ag-free BIOCHIP expressing cells	P3HR1, native/rec. EU 120 P3HR1 EU 120 EU 33 Raji	10 x 01 (test system) 10 x 02 (test system) 20 x 01 (test system) 20 x 02 (test system)
	format 1001: per slide one patient format 1002: per slide two patients				
FI 279a-1005-2 G FI 279a-1010-2 G FI 279a-2010-2 G FI 279a-1005-2 M FI 279a-1010-2 M FI 279a-2010-2 M	"Crimean Congo fever virus Mosaic 2" CCHFV-GPC CCHFV-N	IgG IgM	3 BIOCHIPs per field: transfected cells transfected cells control transfection	EU 90 EU 90 EU 90	10 x 05 (test system) 10 x 10 (test system) 20 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 10 (test system)
FI 280a-1005 G FI 280a-1010 G FI 280a-1005 M FI 280a-1010 M	Rift Valley fever virus (RVFV)	IgG IgM	infected and non-infected cells (2 BIOCHIPs per field)	EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 2821-1001-1 G FI 2821-1002-1 G FI 2821-2002-1 G FI 2821-1001-1 M FI 2821-1002-1 M FI 2821-2002-1 M	"Respiratory Tract Profile 1" (consisting of 21 different substrates)	IgG IgM	field A: verification BIOCHIP, RSV, Adenovirus type 3, Influenza virus type A (H1N1 and H3N2) field B: Influenza virus type B, Parainfluenza virus type 1, 2, 3 field C: Parainfluenza virus type 4, Bordetella pertussis and parapertussis, Mycoplasma pneumoniae field D: Coxsackie virus type B1 and A7, Echo virus type 7, Chlamydia pneumoniae field E: Haemophilus influenzae*, Klebsiella pneumoniae*, Legionella pneumophila serotype 1* and 12*		10 x 01 (test system) 10 x 02 (test system) 20 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) 20 x 02 (test system)
FI 2822-1001-1 G FI 2822-1002-1 G FI 2822-1001-1 M * FI 2822-1002-1 M *	"Exanthema Profile 1" (consisting of 21 different substrates)	IgG IgM	field A: verification BIOCHIP, HHV-6, Rubella virus*, Measles virus, Mumps virus field B: VZV, EBV-CA, EBV-EA, Treponema pallidum field C: HSV-1 and -2, Coxsackie virus type B1 and A9 field D: Echo virus type 7, Borrelia afzelii, burgdorferi (CH), garinii field E: CMV, Candida albicans, krusei*, tropicalis*		10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system)
FI 2823-1001-1 G * FI 2823-1002-1 G * FI 2823-1001-1 M * FI 2823-1002-1 M *	"Lymphadenitis Profile 1" (consisting of 21 different substrates)	IgG IgM	field A: verification BIOCHIP, HIV-1* and 2*, HHV-6, Rubella virus* field B: measles virus, Mumps virus, Adenovirus type 3, Parainfluenza virus type 1 field C: EBV-CA, EBV-EA, Toxoplasma gondii, Treponema pallidum field D: HSV-1 and -2, CMV, Coxsackie virus type B5 field E: Coxsackie virus type A9, Bartonella henselae, Chlamydia trachomatis and pneumoniae		10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system)

*) Currently not available as IVD in the European Union.

Infectious serology

Diagnostics for Indirect Immunofluorescence: Infectious Serology

Order No.	Antibodies against	Ig Class	Substrate	Species	Format Slides x Fields
FI 2824-1001-1 G FI 2824-1002-1 G FI 2824-1001-1 M * FI 2824-1002-1 M *	"Central Nervous System Profile 1" (consisting of 21 different substrates)	IgG IgM	field A: verification BIOCHIP, Rubella virus*, Measles virus, Mumps virus, VZV field B: Adenovirus type 3, EBV-CA, Treponema pallidum, Toxoplasma gondii field C: HSV-1 and -2, Coxsackie virus type B1 and A7 field D: Echo virus type 7, Borrelia afzelii, burgdorferi (CH), garinii field E: CMV, Haemophilus influenzae*, Listeria monocytogenes 1/2a und 4b		10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system)
FI 2825-1001-1 G FI 2825-1002-1 G FI 2825-1001-1 M FI 2825-1002-1 M	"Myocarditis Profile 1" (consisting of 17 different substrates)	IgG IgM	field A: verification BIOCHIP, Mumps virus, Adenovirus type 3, Influenza virus type A (H1N1 and H3N2) field B: Influenza virus Typ B, Parainfluenza virus type 1 and 2, Mycoplasma pneumoniae field C: CMV, Coxsackie virus type B1 and A16, Echo virus type 7 field D: Borrelia afzelii, burgdorferi (CH), garinii, Chlamydia pneumoniae		10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system)
FI 2826-1001-1 G FI 2826-1002-1 G FI 2826-1001-1 M FI 2826-1002-1 M	"Infectious Arthritis Profile 1" (consisting of 13 different substrates)	IgG IgM	field A: verification BIOCHIP, VZV, Influenza virus type A (H1N1 and H3N2) and B field B: Yersinia enterocolitica O:3*, O:6*, O:9*, Toxoplasma gondii field C: Borrelia afzelii, burgdorferi (CH), garinii, Chlamydia trachomatis		10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system)
FI 2861-1003 A FI 2861-1005 A FI 2861-1010 A FI 2861-1003 G FI 2861-1005 G FI 2861-1010 G FI 2861-1003 M FI 2861-1005 M FI 2861-1010 M	Candida albicans	IgA IgG IgM	fungus smear	Candida albicans	10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 03 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 291a-1005 G * FI 291a-1010 G * FI 291a-1005 M * FI 291a-1010 M *	Sindbis virus	IgG IgM	infected and non- infected cells (2 BIOCHIPS per field)	EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)
FI 293a-1005 G FI 293a-1010 G FI 293a-2005 G FI 293a-1005 M FI 293a-1010 M FI 293a-2005 M FK 293a-1005 FK 293a-1010 FK 293a-2005	Chikungunya virus (CHIKV)	IgG IgM	infected and non- infected cells (2 BIOCHIPS per field)	EU 14	10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 05 (test system) 10 x 10 (test system) 20 x 05 (test system) 10 x 05 (single slides) 10 x 10 (single slides) 20 x 05 (single slides)
FI 293a-1005-1 G FI 293a-1010-1 G FI 293a-1005-1 M FI 293a-1010-1 M	"Arboviral Fever Mosaic 1" Chikungunya virus (CHIKV) Japanese encephalitis virus (JEV) Dengue virus types 1 - 4 (DENV)	IgG IgM	6 BIOCHIPS per field: infected cells infected cells infected cells	EU 14 EU 14 EU 14	10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system)

*) Currently not available as IVD in the European Union.